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ABSTRACT 
The pancreatic β cell relies on appropriate Ca2+ entry through voltage-gated calcium (CaV) 
channels to accomplish its unique function insulin secretion and to guarantee its viability. 
Well-regulated β cell CaV channels are critical to ensure adequate functional β cell mass, 
thereby maintaining adequate insulin release and glucose homeostasis in the body. When β 
cell CaV channels mediate insufficient or excessive Ca2+ influx due to either inherited or 
acquired defects, β cell becomes malfunctioning and even dies. Type 1 diabetic (T1D) 
serum hyperactivates β cell CaV1 channels driving Ca2+-dependent β cell apoptosis via 
previously unappreciated mechanisms. The present PhD work has mechanistically dissected 
T1D serum-induced hyperactivation of CaV1 channels in the β cell by combining patch-
clamp techniques, confocal microscopy, as well as molecular and cellular approaches. It 
reveals the following findings: 
Functional CaV1.3 channels reside in 20 % of mouse islet CaV1.2-/- β cells. They 
characteristically show a large unitary Ba2+ conductance with long-lasting openings in 
plasma membrane patches of islet cells endowed with undetectable voltage-gated Na+ 
currents, larger cell capacitance (> 7 pF) and insulin mRNA. These observations pinpoint β 
cell-specific CaV1.2-/- mice as a convenient small animal model for investigation of human 
β cell CaV1.3 channel-related disorders such as T1D serum-induced hyperactivation of β 
cell CaV1.3 channels. 
T1D serum hyperactivates both CaV1.2 and CaV1.3 channels by elevating their 
conductivity and number in the β cell plasma membrane. This finding emphasizes that both 
CaV1.2 and CaV1.3 channels are potential druggable targets for prevention of Ca2+ 
overload-induced β cell death. 
Apolipoprotein CIII (ApoCIII) in T1D serum is electrophysiologically validated to be 
the actual factor enhancing CaV channel currents in the β cell. This validation opens up the 
possibility to deplete or neutralize ApoCIII in T1D serum for medical intervention of CaV 
channel hyperactivation-driven β cell destruction. 
ApoCIII activates both PKA and Src kinase in a scavenger receptor class B type I/β1 
integrin-dependent fashion to selectively hyperactivate β cell CaV1 channels without 
altering β cell CaV1 channel expression. ApoCIII-induced hyperactivation of β cell CaV1 
channels results from the enriched density and increased activity of functional CaV1 
channels in the β cell plasma membrane. This newly-identified signaling pathway shows 
great potential as a set of novel druggable targets for prevention of Ca2+-dependent β cell 
death in association with diabetes. 
The key endocytic protein syndapin I/PACSIN 1 (PCS1) is richly expressed in β cells to 
govern endocytic activity. PCS1-mediated endocytosis acts as a homeostatic control system 
to fine-tune the CaV1 channel density in the β cell plasma membrane. These findings add a 
new layer of complexity to the mechanisms of β cell CaV1 channel regulation. 
ApoCIII impairs both constitutive and regulated β cell endocytosis with no influence on 
PCS1 expression. Consequently, ApoCIII abrogates PCS1-dependent endocytic trafficking, 
thereby accumulating excessive CaV1 channels in the β cell plasma membrane. These 
results delineate a novel mechanism of Ca2+-dependent β cell destruction in diabetes 
development and reveal a promising and attractive option to counteract the critical 
diabetogenic process of Ca2+-dependent β cell death. 
Overall, the aforementioned findings depict a mechanistic picture of how ApoCIII 
renders CaV1 channels highly enriched and excessively activated in the β cell plasma 
membrane, thereby resulting in pathologically exaggerated Ca2+ influx and Ca2+-dependent 
β death. These findings lay the foundation for novel treatment strategies for diabetes. 
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1 INTRODUCTION 
The voltage-gated calcium (CaV) channel resides in all types of excitable cells and some 
non-excitable cells. It controls a diverse range of physiological processes. Its abnormality 
causes various pathological conditions leading to neurological disorders, cardiovascular 
diseases and metabolic dysfunctions [1-4]. The electrically excitable β cell employs 
multiple types of CaV channels to govern its function and viability. The β cell CaV channel-
mediated Ca2+ influx takes center stage in insulin secretion and plays a unique role in 
glucose homeostasis. Inherited or acquired defects in β Cell CaV channels impair β cell 
function and in particular insulin secretion, and even drive β cell destruction resulting in 
diabetes [1-4]. Type 1 diabetic (T1D) serum hyperactivates β cell CaV1 channels causing 
Ca2+-dependent β cell apoptosis via previously unappreciated mechanisms [1-3, 5, 6]. The 
present PhD work has mechanistically dissected T1D serum-induced hyperactivation of 
CaV1 channels in the pancreatic β cell by combining patch-clamp techniques, confocal 
microscopy, as well as molecular and cellular approaches. 
1.1 DIABETES 
Diabetes, also known as diabetes mellitus in full, refers to a group of metabolic diseases 
characterized by hyperglycemia [7, 8]. Marked hyperglycemia results in the specific 
symptoms of diabetes, such as increased urinary frequency (polyuria), thirst (polydipsia), 
hunger (polyphagia) and unexplained weight loss [7, 8]. Over time, untreated 
hyperglycemia often leads to diabetes complications including retinopathy, nephropathy, 
neuropathy, cardiovascular damage, etc [7, 8]. Hyperglycemia and diabetes are important 
causes of mortality and morbidity worldwide [9]. 
1.1.1 Classification of diabetes 
Diabetes is caused by insulin deficiency, insulin resistance or both, and categorized into 
four subgroups: type 1, type 2, gestational diabetes and other specific types [7, 8, 10]. T1D 
accounts for about 5-10 % of diagnosed cases of diabetes [7, 8]. This type of diabetes is 
also called childhood-onset diabetes, juvenile diabetes, or insulin-dependent diabetes. It 
occurs due to pancreatic β cell destruction, usually leading to absolute insulin deficiency [7, 
8]. Type 2 diabetes comprises about 90-95 % of diagnosed cases of diabetes [7, 8]. It is also 
named adult-onset diabetes, obesity-related diabetes, and noninsulin-dependent diabetes. 
Type 2 diabetes results from a combination of both insulin resistance and β cell 
dysfunction, but their relative contribution varies not only during the course of the disease, 
but also among individual patients [7, 8]. Distinctions between T1D and type 2 diabetes are 
not always clear, both etiologically and clinically [11]. Some adults are initially diagnosed 
with type 2 diabetes, but slowly progress to T1D characterized by autoimmune β cell 
destruction [11]. This type of diabetes is referred to as “Latent Autoimmune Diabetes in 
Adults (LADA)” [11]. Likewise, some obese adolescents and young adults (<25 years of 
age) can also have the manifestation of traits of both type 1 and type 2, which is termed 
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“type 1.5” or “double diabetes” [11]. “Type 3 diabetes” or “brain diabetes” has been 
proposed for Alzheimer’s disease in terms of insulin resistance in the brain [12]. 
Gestational diabetes occurs in about 2-5 % of all pregnancies and may improve or 
disappear after delivery [7, 8]. It resembles type 2 diabetes and involves a combination of 
relative insulin deficiency and insulin resistance [7, 8]. Other specific types of diabetes 
consist of the remaining cases of diabetes, which do not fit into the aforementioned three 
types [7]. This category arises from a collection of a few dozen individual causes including 
genetic defects of the β cell, genetic impairments of insulin action, diseases of the exocrine 
pancreas, pancreatic endocrinopathies, some genetic/immune disorders, drug/chemical 
insults, and so on [7]. “Maturity Onset Diabetes Of the Young (MODY)” is a typical 
example in this category of diabetes [7]. 
1.1.2 Diagnosis of diabetes 
According to American Diabetes Association, diabetes should be diagnosed by any of the 
following criteria [7]: 
a. Hemoglobin A1C (A1C) is greater than or equal to 6.5 %. Test scores should be 
achieved in a laboratory using a method that is certified by National Glycohemoglobin 
Standardization Program and standardized to the Diabetes Control and Complications Trial 
assay [7]. 
b. Fasting plasma glucose is greater than or equal to 126 mg/dl (7.0 mmol/l). A subject 
should have no caloric intake for at least 8 h [7]. 
c. Two-hour plasma glucose is greater than or equal to 200 mg/dl (11.1 mmol/l) during 
an oral glucose tolerance test. The measurement should be performed using a glucose load 
containing the equivalent of 75 g anhydrous glucose dissolved in water in line with the 
World Health Organization’s guidelines [7]. 
d. A random plasma glucose is greater than or equal to 200 mg/dl (11.1 mmol/l) when a 
patient suffers from classic symptoms of hyperglycemia or hyperglycemic crisis [7]. 
Criteria a-c should be confirmed by repeat testing if unequivocal hyperglycemia is 
absent [7]. 
1.1.3 T1D 
T1D is classified broadly into immune mediated (type 1 A) and idiopathic (type 1 B) forms 
[7, 13]. The minority of T1D is idiopathic. This form of T1D shows clear signs of 
insulinopenia with an unknown etiology and requires insulin replacement therapy. It is 
strongly inherited, lacks evidence for β cell autoimmunity, and is not human leukocyte 
antigen (HLA) associated. The majority of T1D is immune mediated as evidenced by the 
presence of an inflammatory infiltrate in the islets, a strong linkage with certain alleles of 
the major histocompatibility complex (MHC) and autoantibodies that react with islet cell 
autoantigens [7, 13]. The present PhD thesis deals with type 1A diabetic serum-induced 
hyperactivation of β cell voltage-gated calicium (CaV) channels. The term “type 1A 
diabetes” is hereafter replaced by “T1D”. 
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1.1.3.1 Pathogenesis of T1D 
The human MHC is called HLA complex, which is located on chromosome 6 and contains 
over 200 genes encoding HLA class I and class II molecules [7, 13, 14]. Both HLA class I 
and class II genes are linked to T1D. The class II genes DQA, DQB and DRB by far show 
the strongest linkage to the disease [7, 13, 14]. A high percentage of sera from newly 
diagnosed T1D patients contain autoantibodies against islet cells, insulin, the 65-kD 
isoform of glutamic acid decarboxylase (GAD65), insulinoma-associated protein 2 (IA-2) 
and 2β (IA-2β) and zinc transporter 8 (ZnT8) [7, 13, 14]. These autoantibodies appear quite 
a few months or years before the onset of the clinical disease. They have turned out to be 
excellent diagnostic and predictive markers for T1D. However, it is not conclusively 
verified, but just generally thought that they play only a minor role, if any, in the actual 
pathogenesis of the disease [7, 13, 14]. The cell-mediated immune response is believed to 
be responsible for β cell destruction [13, 14]. The immune-mediated β cell destruction 
relies on CD8+ cytotoxic and CD4+ helper lymphocytes. Antigen-specific CD8+ T cells 
recognize islet cell antigens in a complex with HLA class I molecules on the surface of β 
cells. This leads to up-regulation of a number of co-stimulatory molecules such as 
FAS/FASL and activation of one or more of several different effector pathways, e.g., 
FAS/FASL and perforin/granzyme to drive β cell apoptosis [13, 14]. In contrast, antigen-
specific CD4+ T cells indirectly kill β cells by recognizing autoantigens in association with 
HLA class II molecules on the surface of antigen-presenting cells (APCs) such as 
macrophages and dendritic cells. This recognition up-regulates co-stimulatory molecules, 
e.g., CD28/CD80 and stimulates the release of a variety of cytokines, such as interferon γ, 
tumor necrosis factor α and nitric oxide, from both CD4+ T cells and antigen-presenting 
cells resulting in apoptosis of nearby β cells [13, 14]. 
1.1.3.2 Triggers for autoimmune β cell destruction in T1D 
Triggers for the autoimmune-mediated destruction of β cells are not known. Immunologic, 
genetic and environmental factors have been implicated [13, 14]. T cells develop 
immunocompetence in the thymus [14]. Only a small proportion of newly generated T 
cells, which receive a weak, low affinity signal from an HLA-autoantigen complex, are 
capable of passing thymic selection as antigen-specific T cells and migrating to peripheral 
organs throughout the body including the pancreas. Normally, these T cells lie dormant and 
remain under strict regulatory control [14]. In the scenarios where either they come in 
contact with cognate autoantigens presented by β cells or APCs in the pancreas or the 
regulatory controls fail, these dormant, antigen-specific T cells become activated to initiate 
the autoimmune cascade of β cell killing. Thus, immune dysregulation may act as one of 
the triggers for autoimmunity in T1D [13, 14]. With regard to genetic factors, a 
combination of several different genes is involved [13, 14]. More than 40 genomic loci 
have been linked with influencing T1D risk [13]. Variations in HLA genes are an important 
genetic risk factor, but alone they do not account for the disease and other genes are 
involved [13, 14]. In addition, environmental factors such as delivery by cesarean section, 
high birth weight, vitamin D deficiency, viral infections, obesity and environmental 
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toxicants, may undergo complex interactions to drive β cell autoimmunity and cause 
clinical T1D [13, 15]. 
1.2 APOCIII 
Apolipoprotein CIII (ApoCIII) belongs to the family of amphiphilic apolipoproteins in the 
circulation [16-18]. These apolipoproteins bind to lipid vesicles through their amphiphilic 
α-helices to create different plasma lipoprotein particles, including chylomicrons, very-low-
density lipoproteins (VLDLs), low-density lipoproteins (LDLs) and high-density 
lipoproteins (HDLs) [16-18]. Hence, the apolipoproteins are often described as lipid 
transport vehicles through the aqueous circulatory system in the body [16-18]. Besides lipid 
transport, the apolipoproteins also serve as receptor ligands, lipid transfer carriers and 
enzyme cofactors to regulate cellular uptake and metabolism of lipoproteins [16-18]. 
1.2.1 Molecular and biochemical aspects of ApoCIII 
ApoCIII is an 8.75 kDa protein composed of 79 amino acid residues [16-18]. In humans, 
this relatively small protein is encoded by the ApoCIII gene clustered with the ApoAI, 
ApoAIV and ApoAV genes on chromosome 11q23 [19]. ApoCIII gene expression is 
subjected to complex regulation. Insulin signaling inhibits both hepatic and intestinal 
ApoCIII expression via phosphorylation-dependent nuclear exclusion of the transcription 
factor forkhead box protein O1 (FoxO1). This transcription factor stimulates hepatic 
ApoCIII expression by binding to its consensus site in the ApoCIII promoter [20]. 
Streptozotocin-induced diabetic mice without and with insulin treatment display increased 
and decreased hepatic ApoCIII mRNA levels, respectively [21]. Both insulin-deficient non-
obese diabetic (NOD) mice and insulin-resistant db/db mice exhibit increased ApoCIII 
levels due to deregulated FoxO1 expression in their livers and intestines [20]. Activation of 
peroxisome proliferator-activated receptor α (PPARα) with fibrates drastically decreases 
hepatic ApoCIII expression [22, 23]. Interestingly, the regulatory element of a nuclear 
factor κ-light-chain-enhancer of activated B cells (NF-κB) is located 150 nucleotides 
upstream from the transcriptional start site of the ApoCIII gene [24]. Activated NF-κB 
binds to this regulatory element to up-regulate ApoCIII expression [24]. 
ApoCIII is synthesized predominantly in the liver and to a minor extent in the intestine. 
Liver and intestinal cells release this apolipoprotein into the blood [16, 17]. Recent work 
has also revealed that ApoCIII can be produced in mouse islet cells [25, 26]. ApoCIII can 
be posttranslationally glycosylated at threonine 74 and exists as three isoforms: ApoCIII0, 
ApoCIII1 and ApoCIII2, which are covalently linked with 0, 1 and 2 sialic acid residues, 
respectively, and account for 10, 55 and 35 %, respectively, of total ApoCIII in the 
circulation [27]. ApoCIII contains six amphiphilic α-helixes, each consisting of about 10 
residues. The three-dimensional nuclear magnetic resonance structure of ApoCIII has been 
resolved when it complexes with sodium dodecyl sulfate micelles, mimicking its natural 
lipid-bound state. The six amphiphilic α-helixes assemble into a necklace-like chain 
wrapping around the sodium dodecyl sulfate micelle surface [16]. 
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1.2.2 ApoCIII inhibition on triglyceride and cholesterol metabolism 
Classically, ApoCIII serves as an effective inhibitor of triglyceride metabolism through the 
following mechanisms. ApoCIII is situated on the surface of chylomicrons, LDLs and 
HDLs [16, 17]. It prevents triglyceride-rich lipoproteins from approaching the negatively 
charged cell surface by displacing apolipoprotein E or changing apolipoprotein E 
conformation [16, 28]. Consequently, the cell surface-attached lipoprotein lipase and 
plasma membrane-localized apolipoprotein E receptors can no longer reach triglycerides 
and apolipoprotein E in lipoproteins to carry on triglycerides hydrolysis and the endocytic 
clearance of triglyceride-rich lipoproteins, respectively. ApoCIII displaces lipoprotein 
lipase from lipid droplets and competes with the lipoprotein lipase activator apolipoprotein 
CII for the lipid/water interface, thereby suppressing lipoprotein lipase activity [29]. 
ApoCIII also impedes the selective uptake of cholesteryl esters from LDLs and HDLs by 
binding to the scavenger receptor class B type I (SR-BI), and hampers the endocytosis of 
cholesterol-rich LDLs by prevention of apolipoprotein B binding to LDL receptors [30-32]. 
1.2.3 ApoCIII-induced dyslipidemia and inflammation 
ApoCIII inhibition on lipoprotein lipase results in impaired triglyceride metabolism and 
clearance [19, 33]. Mice carrying a disrupted ApoCIII gene show 70 % reduction in 
triglyceride levels [19]. Transgenic mice overexpressing human ApoCIII manifest 
hypertriglyceridemia [33]. Elevated plasma ApoCIII concentration is a feature of 
dyslipidemia in obesity and strongly related to cardiovascular risk [34]. A group of 
Ashkenazi Jews with reduced plasma ApoCIII concentration maintains cardiovascular 
health and reaches exceptional longevity [35]. This is not only because of ApoCIII-induced 
dyslipidemia, but also ApoCIII-mediated inflammation [19, 33, 36]. For example, ApoCIII 
promotes the development of arteriosclerosis by facilitating adhesion of monocytes to 
vascular endothelial cells through activation of the inflammatory cascade PKCα/NF-κB/β1-
integrin [37-39]. Actually, ApoCIII is a multifaceted player in cell signaling [30, 37, 39, 
40]. It can bind to distinct cell surface receptors including SR-BI and uncharacterized 
binding sites relaying corresponding signals to their downstream effectors, e.g., β1 integrin, 
pertussis toxin-sensitive G proteins, NF-κB and protein kinases [30, 37, 39, 40]. This 
suggests that ApoCIII participates not only in the inflammatory process, but also other 
molecular and cellular events. 
1.2.4 ApoCIII and diabetes 
Earlier studies indicate that plasma ApoCIII levels are associated with diabetes. There is an 
increase in this apolipoprotein in both T1D and type 2 diabetes [6, 41]. The Ashkenazi Jews 
with decreased plasma ApoCIII levels display greater insulin sensitivity with age [35]. A 
haplotype block carrying genetic variants within the regulatory region of the ApoCIII gene 
promoter is closely associated with T1D. This genetic association likely results from 
increased expression of ApoCIII driven by the genetic ApoCIII gene haplotype [42]. In vivo 
suppression of ApoCIII delays onset of diabetes with doubling the time in the BioBreeding 
rat, a rat model for human T1D. [43]. Interestingly, in ob/ob mouse islets, local insulin 
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resistance promotes ApoCIII production and β cell failure [25, 26]. Although a T-
lymphocyte-mediated autoimmune attack plays a crucial role in the development of T1D, 
diabetogenic serum factors undoubtedly aggravate the disease development on top of the 
autoimmune attack [1-3, 5, 6, 44]. Elevated ApoCIII has been demonstrated to act as such a 
serum factor to drive β cell destruction in T1D [1-3, 5, 6, 45]. 
1.3 CAV CHANNELS 
CaV channels appear in both prokaryotes and eukaryotes, being more diversified in higher 
forms of life. Mammals accommodate multiple types of CaV channels with different gating 
kinetics. Distinct types of CaV channels are selectively distributed among different cell 
types and in different special regions of the plasma membrane to control specific cellular 
activities [1-3, 46-48]. 
1.3.1 Function of CaV channels 
CaV channels are tightly controlled Ca2+-conducting pores in the plasma membrane. 
Membrane depolarization drives a rapid conformational switch of CaV channels from an 
impermeable state to a highly permeable pore. The highly permeable pore allows 
extracellular Ca2+ to rapidly enter the cytoplasm, where Ca2+ functions as a second 
messenger to couple electrical signaling to Ca2+-dependent protein-protein interactions and 
enzymatic responses [1-3, 46-48]. Therefore, the CaV channel-mediated Ca2+ influx governs 
a broad range of cellular processes including exocytosis, endocytosis, muscle contraction, 
synaptic transmission, metabolism and cell fate. It participates in fertilization and regulates 
proliferation, differentiation, and development through the alteration of protein 
phosphorylation, gene expression, and the cell cycle [1-3, 46-49]. Pathophysiologically, 
hyperactivated CaV channels mediate exaggerated Ca2+ influx resulting in Ca2+-dependent 
cell destruction through initiation of apoptosis and necrosis. Disturbed function of CaV 
channels, caused by mutation, altered expression and autoimmune insults, gives rise to a 
series of clinical signs and symptoms, named as calcium channelopathies or calcium 
channel diseases [1-3, 50-53]. 
1.3.2 Physiological and pharmacological properties of CaV channels 
Classical voltage clamp analysis divides CaV channels into low- and high-CaV channels in 
terms of their activation thresholds [54]. The establishment of advanced patch-clamp 
techniques and the discovery of selective CaV channel blockers enable in-depth 
characterization of CaV channels [1-3, 46, 47, 55, 56]. Low-CaV channels display a tiny 
unitary conductance and a transient kinetics of inactivation. Therefore, low-CaV channels 
are also called T-type Ca2+ channels (T for tiny and transient) [1-3, 46, 47, 55, 56]. High-
CaV channels show distinct electrophysiological and pharmacological features which 
subdivide these channels into L-type, N-type, P/Q-type and R-type Ca2+ channels [1-3, 46, 
47, 55, 56]. L-type Ca2+ channels have a larger unitary conductance, mediate long-lasting 
currents (L for larger and long-lasting) and exhibit the typical dihydropyridine (DHP) 
sensitivity [1-3, 46, 47, 55, 56]. N-type Ca2+ channels display smaller unitary conductance, 
  7 
lower activation threshold, and faster inactivation rate than L-type Ca2+ channels, but larger 
unitary conductance, higher activation threshold, and slower inactivation rate than T-type 
Ca2+ channels. Such Ca2+ channels are neither T nor L. Additionally, they were only found 
in neurons. Therefore, these channels were classified as a distinct type named N-type (N for 
neither, nor and neuron). N-type Ca2+ channels are blocked by the peptide blocker ω-
conotoxin GVIA (ω-CTX GVIA), but are insensitive to DHPs [1-3, 46, 47, 55, 56]. P-type 
Ca2+ channels were originally revealed in cerebellar Purkinje cells (P for Purkinje). 
Sequentially, Q-type Ca2+ channels were identified in cerebellar granule cells (Q chosen 
according to alphabetical order). Both are blocked by ω-agatoxin IVA (ω-Aga IVA). The 
former is somewhat more sensitive to ω-Aga IVA and inactivates slightly slower than the 
latter. However, it is difficult to distinguish them. Hence they are combined as P/Q-type 
Ca2+ channels [1-3, 46, 47, 55, 56]. R-type Ca2+ channels were discovered in cerebellar 
granule cells that showed a residual Ca2+ current resistant to the multiple CaV channel 
blockers nimodipine, ω-CTX GVIA, and ω-Aga IVA (R for residual and resistant). R-type 
Ca2+ channels are now no longer resistant to “everything.” They are blocked by the purified 
peptide toxin SNX-482 [1-3, 46, 47, 55, 56]. 
1.3.3 Molecular architecture of CaV channels 
Biochemical examination and molecular biological investigation have substantially 
characterized the architecture of CaV channels [1-3, 46, 47]. The CaV channel is a multi-
subunit protein complex. Typically, it consists of α1, α2δ, β and γ subunits [1-3, 46, 47]. A 
hydrophobic α1 subunit noncovalently associates with a disulfide-linked α2δ dimmer, an 
intracellular phosphorylated β subunit and a transmembrane γ subunit [1-3, 46, 47]. In this 
complex, the α1 subunit contains four homologous transmembrane domains forming a Ca2+ 
conducting pore. Hence, the α1 subunit is known as the pore-forming or principal subunit. 
The homologous transmembrane domain of the α1 subunit consists of six transmembrane 
segments (S1 to S6) and a membrane-associated pore loop (P-loop) between the S5 and S6 
segments, three intracellular linkers, and N- and C-termini. The four homologous domains 
are structured into a Ca2+-conducting pore equipped with activation and inactivation gates 
and controlled by voltage sensors. Four pairs of the S5 and S6 segments along with the P-
loops line the Ca2+-conducting pore. The Ca2+ selectivity of the pore relies on four glutamic 
acid residues situated in the four P-loops of high-CaV channels or two glutamic and two 
aspartic acid residues localized in the corresponding positions of low-CaV channels. The S4 
segments function as the principal voltage sensors in CaV channels. The depolarization-
evoked movement of the voltage sensors results in the conformational change and/or 
physical reposition of activation and inactivation gates to open the channel and to reduce 
channel permeability, respectively [1-3, 46, 47]. 
So far, ten α1 subunits have been identified. They are α1A, α1B, α1C, α1D, α1E, α1F, 
α1G, α1H, α1I and α1S subunits and mediate L- (α1C, α1D, α1F and α1S subunits), P/Q- 
(α1A subunit), N- (α1B subunit), R- (α1E subunit), and T-type Ca2+ currents (α1G, α1H 
and α1I subunits), respectively [1-3, 46, 47]. Other subunits, β, γ and α2δ subunits, do not 
directly participate in the formation of the Ca2+ conducting pore, but regulate the function 
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and trafficking of α1 subunits. Therefore, these subunits are referred to as auxiliary or 
regulatory subunits. To date, four α2δ subunits (α2δ1-4), four β subunits (β1-4) and eight γ 
subunits (γ1-8) have been identified [1-3, 46, 47]. 
1.3.4 Phylogenetic classification of CaV channels 
Comparative amino acid sequence analysis satisfactorily builds the phylogenetic tree of 
CaVα1 subunits, which shows a close relationship between CaVα1 subunit structure and 
function [56]. This phylogenetic tree creates the most accurate and widely-accepted 
nomenclature of CaV channels. The nomenclature categorizes CaV channels into three 
families, CaV1, CaV2 and CaV3. The first one has four members: CaV1.1 (α1S), CaV1.2 
(α1C), CaV1.3 (α1D) and CaV1.4 (α1F). The second one consists of CaV2.1 (α1A), CaV2.2 
(α1B) and CaV2.3 (α1E). The third one comprises CaV3.1 (α1G), CaV3.2 (α1H) and CaV3.3 
(α1I) [56]. Some of them are selectively expressed in specific cell types, e.g., CaV1.1 in 
skeletal muscle and CaV1.4 in retina and T-lymphocytes, while others are widely 
distributed in various cell types throughout the body. They execute unique functions in 
different cell types, such as muscle contraction, neurotransmitter release, and hormone 
secretion [1-3, 46, 47, 55, 56]. 
1.3.5 β Cell CaV channels 
Electrically excitable β cells as a major cellular component of islets of Langerhans control 
glucose homeostasis by secreting insulin, which is the only hormone capable of lowering 
blood glucose in the body [1-4, 57]. The most elementary β cell activity glucose-stimulated 
insulin secretion indispensably relies on β cell CaV channels. General speaking, CaV1.2, 
CaV1.3, CaV2.1, CaV2.2, CaV2.3, CaV3.1 and CaV3.2 channels are present in β cells where 
they conduct all known types of CaV channel currents including L-type, N-type, P/Q-type, 
R-type and T-type [1-4, 57-59]. 
1.3.5.1 Heterogeneous expression of CaV channels in the β cell 
The major type of CaV channels in the β cell is the CaV1 channel, which conducts L-type 
Ca2+ currents [1-4, 57-59]. The mouse islet β cell is equipped with the CaV1 channel as 
evidenced by the presence of L-type Ca2+ currents recorded at the whole-cell and single 
channel level. Whole-cell or unitary L-type Ca2+ currents have been well characterized in 
rat islet β cells. Like other species, human islet β cells also employ the CaV1 channel to 
conduct the principal Ca2+ currents as revealed by whole-cell and single channel analysis 
[1-4, 57-59]. 
The β cell also possesses other types of CaV channels such as the CaV2.1 channel, which 
mediates the P/Q-type Ca2+ currents [1-4]. CaV2.1 channels have been verified in the mouse 
islet β cell by patch-clamp analysis in conjunction with pharmacological dissection [60]. 
The rat islet β cell is also equipped with the CaV2.1 channel [61]. This channel has been 
identified in human islet β cells where 25 % of whole-cell Ca2+ currents are blocked by the 
CaV2.1 channel blocker ω-Aga IVA [62]. The identity and function of the CaV2.2 channel, 
a conduit of N-type Ca2+ currents, are most controversial in β cells [1, 2]. The null effect of 
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the CaV2.2 channel blocker ω-CTX GVIA on the mouse β cell Ca2+ currents denies the 
presence of the CaV2.2 channel [63]. As suggested from cytosolic free calcium 
concentration ([Ca2+]i) measurements in the presence of ω-CTX GVIA, the CaV2.2 channel 
is present in rat islet β cells [64]. It is uncertain whether CaV2.2 channels are expressed in 
human islet β cells [1, 2]. The genetic ablation of the CaV2.3 subunit gene in combination 
with pharmacological manipulations demonstrates that the CaV2.3 channel is expressed in 
the mouse islet β cell and mediates R-type Ca2+ currents [4, 65]. 
Although the low voltage-activated CaV3 channels, conduits of T-type Ca2+ currents, are 
expressed in a wide range of cell types, even in nonexcitable cells, T-type Ca2+ currents are 
absent in the normal mouse islet β cell [1, 2]. However, CaV3 channels appear as a 
phenotype of the diabetes-prone mouse islet β cells from NOD mice [66]. This suggests 
that the CaV3 channel genes are silenced in the normal mouse islet β cell. Such silenced 
genes can be activated in the diabetes-prone milieu in the NOD mouse islet β cell [1, 2, 66]. 
Rat islet β cells are equipped with CaV3 channels [67]. However, whole-cell T-type Ca2+ 
currents mediated by CaV3 channels in the rat islet β cells cannot be easily discriminated 
from high CaV channel currents [1, 2]. Single channel analysis convincingly shows the 
presence of the CaV3 channel in rat islet β cells [68, 69]. Both whole-cell and unitary T-
type Ca2+ currents have been clearly observed in human islet β cells [1, 2, 59]. 
The CaV1 channel is the major β cell CaV channel in all species tested. However, 
obvious interspecies differences in expression of CaV channel types have been verified in β 
cells [1-3]. Primary β cells in different species are equipped with distinct sets of CaV 
channels. For example, CaV3 currents are clearly recorded in the human and rat β cell, but 
not in the mouse β cell [1-3]. It is worthwhile to note that much controversy still remains 
with respect to interspecies differences in expression of CaV channel types in β cells [1-3]. 
One has not yet reached consensus on species-specific expression of CaV2.3 channels in the 
human β cell. Some observations speak in favor of the presence of CaV2.3 channels, 
whereas others argue for the absence of these channels [1-3, 59]. CaV1.2 and CaV1.3 
channels are visualized in β cells including human and rat islet β cells as well as the insulin-
secreting cell lines HIT-15T, INS-1, RINm5F and βTC3 [1-3]. However, it is still uncertain 
whether functional CaV1.3 channels are present in mouse islet β cells [1-3]. This question 
was tackled during my PhD studies. 
1.3.5.2 Physiological roles of CaV channels in the β cell 
β cell CaV channels mediate Ca2+ influx to generate a key electrical signal across the β cell 
plasma membrane and a versatile second messenger in the β cell [1-4]. The former 
constitutes the upstroke or depolarization phase of the β cell action potential [1-4]. The 
latter manifests itself as [Ca2+]i in the β cell. [Ca2+]i, resulting from CaV channel-mediated 
Ca2+ influx and its evoked Ca2+ release from intracellular stores, varies both spatially and 
temporally to form a variety of dynamic signals [1-4]. These signals activate Ca2+-
dependent enzymes and Ca2+-binding proteins [1-4]. By means of these signals, β cell CaV 
channels participate in the regulation of all known molecular and cellular events including 
gene transcription, protein phosphorylation, exocytosis, endocytosis, proliferation, 
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differentiation, metabolism, survival and growth to guarantee β cell function and viability 
[1-4]. Genetic or pharmacological ablation of β cell CaV channels leads to overt defects in β 
cell development [2, 4, 65, 70]. The CaV1.3 and CaV2.3 channel knockout markedly 
disturbs postnatal pancreatic β cell generation and evidently impedes islet cell 
differentiation, respectively [4, 65, 70]. The CaV1 channel blockers D-600 and diltiazem 
significantly retard β cell proliferation [71, 72]. Hyperpolarization of β cells with the 
selective KATP channel opener diazoxide noticeably slows down β cell growth [71]. 
Expression of numerous β cell genes critically depends on Ca2+ influx through CaV 
channels [2, 73-76]. For example, CaV channel blockers effectively abrogate insulin gene 
transcription induced by glucose stimulation [2, 73, 74]. Most importantly, β cell CaV 
channels take center stage in glucose-stimulated insulin secretion to maintain glucose 
homeostasis [1-4]. For further details, see the section Roles of CaV channels in insulin 
secretion below. 
1.3.5.2.1 Roles of CaV channels in insulin secretion 
β Cell CaV channels participate in formation of a molecular network to precisely govern 
glucose-stimulated insulin secretion [1-4]. Blood glucose enters β cells via low-
affinity/high-capacity glucose transporters. Subsequently glucose metabolism occurs in 
these cells leading to activation of a series of signal transduction events [1-4]. An increase 
in the ATP/ADP ratio, resulting from glucose metabolism, shuts off ATP-sensitive K+ 
(KATP) channels, resulting in plasma membrane depolarization. This in turn leads to 
opening of CaV channels, allowing extracellular Ca2+ to enter the β cell. The consequent 
increase in [Ca2+]i initiates direct interactions between exocytic proteins situated in the 
insulin secretory granule membrane and those localized in the plasma membrane. Such 
protein-protein interactions cause fusion of insulin secretory granules with the plasma 
membrane and thereby insulin secretion [1-4]. Actually, pancreatic islets release insulin in a 
biphasic manner in response to a step increase in glucose. This dynamic process displays a 
rapid initial phase, lasting for about 10 minutes, followed by a nadir, and subsequently a 
gradually increasing second phase, reaching a plateau after a further 25 to 30 minutes [2, 4, 
77, 78]. Available observations support that all types of β cell CaV channels participate in 
the regulation of glucose-stimulated insulin secretion and that different types of β cell CaV 
channels selectively regulate the two distinct phases of dynamic insulin secretion [1-4, 58, 
77-80]. 
The CaV1 channel plays a predominant role over other types of β cell CaV channels in 
Ca2+ triggered insulin exocytosis. Ca2+ influx through the CaV1 channel underlies 60-80 % 
of glucose-induced insulin secretion from mouse, rat and human islets [1-4]. CaV1 channels 
regulate both phases of insulin secretion but take a more prominent part in triggering 
insulin release during the first phase in the mouse islet [1-4]. The distinct contribution of 
CaV1.2 and CaV1.3 subtypes to insulin exocytosis in the human and rat islet β cell is not 
known, due to lack of appropriate experimental approaches [1-4]. 
CaV2.1 channels are heavily involved in glucose-stimulated insulin secretion from rat 
and human β cells [1-4]. The CaV2.1 channel blocker ω-Aga IVA partially inhibits high 
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CaV channel currents in the rat β cell and consequently reduces the DHP-resistant 
component of glucose-induced insulin secretion by about 30 % [1-4]. The human islet 
displays about 31 % reduction in the glucose-induced secretory response following 
incubation with ω-Aga IVA [59]. No definite verdict can be reached on the role of CaV2.2 
channels in insulin secretion [1-4]. It has been shown that glucose-induced insulin secretion 
in human islets is insensitive to the CaV2.2 channel blocker ω-CTX GVIA. On the contrary, 
it has also been revealed that this blocker inhibits insulin secretion from human islets and 
the second phase glucose-induced insulin secretion from rat islets. However, it was 
speculated that the inhibitory effect of ω-CTX GVIA on the second phase insulin secretion 
may be attributed to toxic effects on the secretory process rather than effects on the CaV2.2 
channel-mediated Ca2+ entry. Nevertheless, this is unlikely since the ω-CTX GVIA-treated 
islets exhibit normal first phase insulin secretion and intact high K+-evoked insulin 
exocytosis. Further investigations demonstrate that block of β cell CaV2.2 channels by ω-
CTX GVIA significantly dampens the generation of ATP. It is therefore likely that CaV2.2 
channel-mediated Ca2+ entry underlies Ca2+-dependent glucose metabolism and thereby 
facilitation of the generation of ATP, which is important for second phase insulin secretion 
[1-4]. Application of the CaV2.3 channel blocker SNX-482 manifests that CaV2.3 channels 
regulate insulin secretion from both INS-1 cells and mouse islets [2-4, 65]. Islets incubated 
with SNX-482 or isolated from CaV2.3-/- mice display a severe impairment in second phase 
glucose-stimulated insulin secretion, but a normal profile of first phase insulin secretion. 
The above results indicate that unlike the β cell CaV1 channels, which are situated at the 
exocytic site, the CaV2.3 channel seems to be distant from these sites in the β cell. Ca2+ 
influx through the CaV2.3 channel selectively regulates second phase insulin secretion, 
likely due to facilitation of insulin secretory granule trafficking from the reserve pool to the 
readily releasable pool/immediately releasable pool [2-4, 65]. 
The CaV3 channel-mediated Ca2+ entry likely contributes to the regulation of stimulus-
secretion coupling in the β cell [1-3]. Block of CaV3 channels with lower concentrations of 
NiCl2 significantly inhibits insulin secretion from INS-1 cells. Both glucose- and K+-
induced insulin secretion in perifused rat islets are attenuated by the nonselective CaV 
channel antagonist flunarizine, which targets both CaV1 and CaV3 channels [1-4]. 
It is tempting to speculate that β cell CaV1 channels self-organize into triplets and 
physically associate with syntaxin 1 and SNAP-25 to form local high [Ca2+]i-driven 
exocytic sites, whereas CaV2 channel-mediated Ca2+ influx contributes to global [Ca2+]i to 
recruit insulin granules to exocytic sites [81, 82]. The differential localization and 
organization of CaV1 and CaV2 channels provide a reasonable explanation for selective 
regulation of first and second phase glucose-stimulated insulin secretion by CaV1 and CaV2 
channels [81, 82]. 
CaV channels not only mediate Ca2+ entry to evoke insulin exocytosis, but also serve as 
mechanical components of the β cell exocytic machinery independent of Ca2+ influx [83-
85]. The conformational change of the CaV1.2 subunit, driven by Ca2+ binding and 
depolarization, acts as a trigger to release an appreciable amount of insulin prior to Ca2+ 
influx. This has been substantiated by the following studies. The inorganic CaV1 channel 
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blocker La3+ binds to the polyglutamate motif (EEEE) in the selectivity filter of the CaV1 
subunit and thereby blocking Ca2+ influx. Unexpectedly such a La3+ binding appreciably 
potentiates glucose-stimulated insulin secretion from rat pancreatic islets and ATP release 
in INS-1E cells. The effect is not involved in Ca2+ release from intracellular stores and 
abolished by the organic CaV1 channel blocker nifedipine. This indicates that the 
conformational switch of the CaV1.2 subunit evoked by La3+ binding to the EEEE motif 
suffices to support glucose-stimulated insulin secretion at the very early phase [84, 85]. 
Intriguingly, the CaVβ3 subunit does not serve as a building block of β cell CaV channels. 
Instead, it interplays with the intracellular Ca2+ release machinery in a negative manner to 
restrain inositol 1,4,5-trisphosphate receptor-mediated Ca2+ mobilization from intracellular 
stores in the β cell and thus hinders insulin secretion [83]. 
1.3.5.2.2 Regulation of CaV channels in the β cell 
The conductivity and density of β cell CaV channels undergo complex and exquisite 
regulation to guarantee Ca2+-dependent β cell viability and ensure Ca2+-dependent β cell 
activity and in particular glucose-stimulated insulin secretion, thereby satisfying various 
insulin demands of the body under different metabolic conditions [1-4]. Different types of 
important regulatory mechanisms of β cell CaV channels coordinate with each other in the 
context of physiology [1-4]. 
1.3.5.2.2.1 Protein phosphorylation 
β cell CaV channels possess multiple protein phosphorylation sites and are typical substrates 
of multiple protein kinases and phosphatases. Phosphorylation drives conformational 
switch of CaV channels resulting in alteration in their Ca2+ conductivities. Activation of 
PKA up-regulates the activity of β cell CaV1 channels [2, 86-89]. PKC activation brings 
about complicated regulation on β cell CaV channels [90-92]. Pharmacological deprivation 
of PKC decreases L-, P/Q- and non-N-type Ca2+ currents to the same extent in insulin-
secreting RINm5F cells. Acute activation of PKC induces a marginal increase in CaV 
channel currents, which are predominantly mediated by CaV1 channels, only in a small 
proportion of RINm5F cells (24 %) [2]. The PKG activator cGMP elevates CaV1 channel 
activity in rat pancreatic β cells [93]. However, the role of PKG-dependent phosphorylation 
in this case remains to be clarified since cGMP can directly act on CaV channels bypassing 
PKG [2, 94]. Likewise, it is not clear if calcium/calmodulin-dependent kinase II (CaMKII) 
catalyzes β cell CaV channel phosphorylation. The non-specific CaMKII inhibitors KN-62 
and KN-93 do abrogate β cell CaV channel activity [95, 96]. However, these reagents can 
produce a direct action on β cell CaV channels without CaMKII involvement [2]. Inhibition 
of protein phosphatases with okadaic acid slightly elevates under basal conditions, but 
considerably increases CaV channel activity on top of activation of PKA in mouse 
pancreatic β cells [97]. This indicates that mouse β cell CaV channels just stay marginally 
phosphorylated under basal conditions [1-4]. 
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β cell CaV channels are subjected to tyrosine phosphorylation [2, 98-101]. The nerve 
growth factor signaling pathway participates in β cell CaV channel regulation [2, 98, 99]. 
Long-term incubation (5-7 days) with nerve growth factor enriches the density of CaV1 
channels in the β cell plasma membrane, whereas the acute administration of this nerve 
growth factor promotes the activity of these channels [2, 98, 99]. Activation of insulin 
receptors with the insulin mimetic L-783,281 induces an increase in [Ca2+]i in the mouse 
pancreatic β cell. The effect is significantly abrogated by CaV1 channel blocker but no long 
occurs in insulin receptor substrate-1-knockout β cells [2, 101]. This opens up the 
possibility that acute activation of insulin receptors may up-regulate β cell CaV channel 
activity [2]. It is intriguing to verify this possibility with experimental approaches such as 
patch-clamp analysis. 
1.3.5.2.2.2 G proteins and their downstream signals 
Various G protein-coupled receptors, such as glucagon, glucagon-like peptide-1, 
somatostatin, opioid, galanin, adrenergic and muscarinic receptors, reside in the β cell 
plasma membrane to form complex signal systems with other plasma membrane proteins 
including CaV channels [2, 63, 102-119]. These receptors engage their partner G protein to 
serve as a brake on β cell CaV channel activity through physical association of G proteins 
with CaV channel pore-forming subunits. They also fine-tune β cell CaV channel activity by 
interacting with protein kinases and second messengers. Activation of glucagon, glucagon-
like peptide-1 and opioid receptors augments β cell CaV channel activity, whereas 
stimulation of galanin and α2-adrenergic receptors diminishes it. Concerning muscarinic 
receptors, their activation can lead to either the enhancement or reduction of β cell CaV 
channel activity dependent on cell types [2]. 
1.3.5.2.2.3 Syntaxin 1A, SNAP-25 and synatotagmin 
Key exocytic proteins such as syntaxin 1A, SNAP-25 and synatotagmin are located in close 
proximity to β cell CaV1.2 and CaV1.3 channels in the β cell plasma membrane where they 
physically and functionally interact with each other to form an exocytic signalosome in β 
cells [1-3, 120, 121]. This signalosome bidirectionally conveys messages to regulate both β 
cell CaV1 channel activity and exocytic protein functionality [1-4, 120-122]. 
Syntaxin 1A have been demonstrated to interact with β cell CaV1.3 channels [1-3, 121]. 
Syntaxin 1A and CaV1.3 subunit not only colocalize in the β cell plasma membrane, but 
also are physically associated to form the syntaxin 1A/CaV1.3 subunit complex. 
Importantly, immunointerruption with anti-syntaxin 1A antibodies, which interferes with 
the formation of the CaV1.3 subunit/syntaxin 1A complex, causes a drastic rundown of β 
cell CaV1 channel activity. Furthermore, this treatment also dampens Ca2+-induced insulin 
exocytosis in permeablized β cells, where CaV1 channels can no longer function. This 
demonstrates that the CaV1.3 subunit/syntaxin 1A complex mediates bidirectional signals to 
regulate insulin secretion through maintenance of both CaV channel activity and exocytic 
protein function [1-3, 121]. 
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Syntaxin 1A and synatotagmin also physically associate with β cell CaV1.2 channels [1-
3, 120]. Similar to the CaV1.3 subunit/syntaxin 1A complex, the CaV1.2 subunit/exocytic 
protein complex plays an important role in the regulation of insulin secretion by mediating 
bidirectional signals. However, signaling through this complex inhibits CaV1.2 channel 
activity. The inhibitory action of syntaxin 1A on CaV1.2 channels is partially counteracted 
by synaptotagmin. Obviously, the physical association of the CaV1.2 subunit with syntaxin 
1A and synatotagmin delicately regulates CaV1.2 channel activity. In the β cell, the 
interruption of the physical association of the CaV1.2 channel with exocytic proteins 
completely blocks depolarization-evoked exocytosis, without significant influence on CaV 
channel activity [1-3, 120]. Clearly, the CaV1.2 subunit/exocytic protein complex also 
participates in maintenance of the efficacy of exocytic protein interaction. 
Both the physical association and the functional interaction of CaV1 channels with 
SNAP-25 have been verified [1-3, 120, 122]. Interestingly, the long N-terminus (SNAP-
25(1-197)) and the short C-terminus of SNAP-25 (SNAP-25(198-206)) regulate L-type 
Ca2+ currents differently. The former stimulates whereas the latter inhibits β cell L-type 
Ca2+ currents. It should be noted that inhibition of L-type Ca2+ currents by SNAP-25(198-
206) is more prominent than stimulation of these currents by SNAP-25(1-197). These 
findings add an additional level of complexity to the regulation of β cell CaV1 channels 
[122]. 
1.3.5.2.2.4 Signals generated from glucose metabolism 
Typically, glucose metabolism activates β cell CaV channels via a KATP channel-dependent 
pathway, which has been described in the section Roles of CaV channels in insulin 
secretion. In addition, glucose metabolism also yields a range of signals to regulate β cell 
CaV channels [1-3]. Acute application of high glucose promotes β cell CaV channel activity 
likely through glucose-metabolism-evoked activation of PKC [123]. Chronic exposure to 
either high or low glucose down-regulates expression of β cell CaV channels [2, 124, 125]. 
Glucose metabolism-derived inositol polyphosphates act as important signaling molecules 
to fine-tune β cell CaV1 channel activity [1, 2, 126]. Elevated inositol hexakisphosphate 
increases β cell CaV1 channel activity via inhibition of protein phosphatases and/or 
activation of the adenylyl cyclase-PKA cascade [1-4, 126, 127]. Complex changes in 
inositol polyphosphates by over-expressing multiple inositol polyphosphate phosphatase in 
a β cell line lead to enhanced CaV1 channel activity [1-3, 128]. 
1.3.5.2.2.5 Transthyretin, fatty acids and cholesterol 
Several components in blood plasma are important to β cell CaV channels. The serum 
protein transthyretin up-regulate β cell CaV channel activity to augment glucose-stimulated 
insulin secretion [129]. Free fatty acids serve as ambivalent regulators of β cell CaV 
channels. The most abundant saturated plasma free fatty acid palmitate stimulates and 
inhibits β cell CaV channel currents at lower and higher concentrations, respectively [130]. 
Cholesterol also executes dual actions on β cell CaV channels [131, 132]. Chronic inhibition 
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of cholesterol biosynthesis gives rise to a significant reduction of β cell cholesterol. The 
resulting loss of cholesterol in β cells reduces both β cell CaV channel activity and insulin 
exocytosis. Cholesterol repletion efficiently reverses the effect resulting from chronic 
inhibition of cholesterol biosynthesis [132]. Incubation of mouse β cells with cholesterol-
rich medium not only dampens glucose-stimulated mitochondrial ATP production, but also 
diminishes β cell CaV channel currents [131]. These studies emphasize that β cell CaV 
channels need the appropriate amount of serum components such as cholesterol and free 
fatty acids for its optimal function. They pinpoint that in vivo experimental approaches are 
indispensable to acquire knowledge on β cell CaV channels in genuine physiology [3]. 
1.3.5.3 Pathophysiological roles of CaV channels in the β cell  
β Cell CaV channels become dangerous when they suffer from either inherited or acquired 
defects. These defective channels undergo exaggerated up- and down-regulation, 
disappearance and appearance, and inadequate redistribution in the β cell plasma 
membrane. They mediate insufficient or excessive Ca2+ influx resulting in β cell 
dysfunction and even β cell destruction since β cell viability and functionality critically rely 
on an appropriate range of [Ca2+]i, considerably contributed by β Cell CaV channel-
mediated Ca2+ influx, at specialized subcellular domains [1-4]. 
1.3.5.3.1 Abnormal function of β cell CaV channels in diabetes 
Abnormal function of β cell CaV channels occurs in diabetic animal models and diabetic 
patients (Yang S-N and Berggren P-O, unpublished observations) [1-3]. Both CaV1 and 
CaV3 currents markedly increase in β cells isolated from neonatal streptozotocin-induced 
diabetic (STZ) rats most likely due to an increase in the activity rather than in the number 
of these channels [133]. In fact, DHP binding sites and expression levels of CaV channel 
subunit genes even decrease in STZ rat β cells [133]. Furthermore, it is difficult to pinpoint 
the functional consequence of the increased activity of CaV channels in STZ rat β cells 
since glucose-stimulated [Ca2+]i response and insulin secretion reduce in STZ rat islets 
[133-135]. Like in the STZ rat, both β cell CaV1 and CaV3 channels undergo 
hyperactivation in the Goto-Kakizaki (GK) rat, an animal model of human type 2 diabetes 
[136, 137]. Indeed, the hyperactivated CaV channels mediate an exaggerated Ca2+ influx, 
but trigger diminished exocytosis in the GK rat β cell [136, 137]. It remains elusive whether 
the hyperactivated CaV channels take charge of reduced functional β cell mass, a hallmark 
feature of the diabetic GK rat. It is tempting to postulate that the hyperactivated CaV 
channels may localize apart from exocytic sites to activate other Ca2+ influx-dependent 
activities, such as Ca2+-dependent β cell death. 
On the contrary, β cell CaV channels suffer from down-regulation in Zucker diabetic 
fatty (ZDF) rats [138]. At the prediabetic stage, CaV1.2 and CaV1.3 mRNAs in ZDF islets 
decrease by 28 and 38 %, respectively, and [Ca2+]i in β cells and insulin-secretory response 
to glucose stimulation are substantially impaired. Unfortunately, CaV channel activity has 
not been characterized in the prediabetic β cell. The scenario becomes far worse in overtly 
diabetic ZDF rats. Their islets show 45 and 53 % reductions in CaV1.2 and CaV1.3 mRNAs, 
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respectively, little [Ca2+]i response to K+ depolarization or glucose stimulation and 
undetectable glucose-stimulated insulin release [138]. Similar down-regulation of 
expression of β cell CaV channel subunit genes also occurs in another type 2 diabetic model 
Otsuka Long-Evans Tokushima fatty (OLETF) rat [139]. CaV1.3, CaVβ2 and β3 subunit 
mRNAs are considerably reduced in diabetic OLETF rat islets. Glucose-stimulated insulin 
release in these islets is significantly blunted. However, CaV channel currents in the OLETF 
rat β cell have not been examined [139]. The aforementioned two cases exemplify that the 
insufficient Ca2+ influx resulting from CaV channel down-regulation severely impairs β cell 
function and probably even disintegrates β cells [1-3]. 
1.3.5.3.2 Phenotypic variation of β cell CaV channels in diabetes 
The types of CaV channels expressed in the β cell are genetically well defined [1-4]. 
However, the diabetic environment can vary the phenotypes of β cell CaV channels [1-4]. 
CaV3 channels do not reside in normal mouse pancreatic β cells, but emerge in pancreatic β 
cells isolated from 8-10 weeks old NOD mice [66]. The newly-expressed CaV3 channels 
are characterized by a fast inactivation (20-30 ms time constants at -20 mV), a lower 
threshold for activation (-50 mV), and a maximal activation at -20 mV. These channel-
mediated Ca2+ influx contributes to a 3-fold increase in basal [Ca2+]i [66]. This phenotypic 
variation likely results from cytokine insults surrounding β cells in the NOD mouse, an 
animal model of human T1D, at 8-10 weeks of age [66, 140-142]. Chronic exposure to a 
cytokine mixture of interferon-γ and interleukin-1β indeed activates expression of CaV3 
channels in β cells from Swiss-Webster mice, a compatible control strain for NOD mice [1-
3, 140]. In addition, cytokine treatment also evokes apoptotic β cell death [1-3, 140]. Such 
an apoptotic effect is efficiently diminished by pharmacological ablation of CaV3 channels 
[1-3, 140]. Obviously, in the context of T1D, cytokines selectively switch on expression of 
β cell CaV3 channels to destroy β cells in cooperation with the pathophysiological Ca2+ 
influx mediated by these newly expressed channels [1-3, 66, 140]. 
1.3.5.3.3 Genetic alteration of β cell CaV channels in diabetes 
Both T1D and type 2 diabetes are polygenic diseases characterized by a progressive 
impairment in functional β cell mass [7, 13, 44, 143]. It is reasonable to consider genes 
critical for insulin secretion and β cell viability, as exemplified by CaV channel genes, as 
possible candidates for diabetes susceptibility [7, 13, 44, 143-146]. Although it is difficult 
to evaluate correlation between CaV channel gene mutations and diabetes, some interesting 
findings have emerged [1, 2, 145-148]. 
In a Japanese family, CaV2.1 subunit gene mutations cause spinocerebellar ataxia type 6 
that is highly associated with type 2 diabetes [1, 2, 147]. Thirteen members in this five-
generation family have suffered from spinocerebellar ataxia type 6. Three out of the five 
patients examined were diagnosed with overt type 2 diabetes. This CaV2.1 subunit mutant 
carries abnormal CAG repeat expansion encoding a polyglutamine tract [1, 2, 147]. 
Characterization of biophysical properties and surface expression of this mutant shows 
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inconsistent results [1, 2, 149, 150]. The work by Toru et al. showed that the 
polyglutamine-containing CaV2.1 subunit expressed in HEK 293 cells displayed a negative 
shift of voltage-dependent inactivation resulting in reduced Ca2+ influx [1, 2, 149]. In 
contrast, Piedras-Renteria et al. reported that the mutant CaV2.1 subunit did not alter its 
biophysical properties, but instead it was expressed more abundantly in the plasma 
membrane in HEK 293 cells, giving rise to higher CaV channel current density as compared 
to the wild-type CaV2.1 subunit [1, 2, 150]. Unfortunately, it is not known how the mutant 
CaV2.1 channel behaves in the β cell to contribute to the development of diabetes 
concurrent with spinocerebellar ataxia type 6 [1, 2, 147]. 
Evaluation of human CaV1.3 subunit gene polymorphisms in 918 Japanese type 2 
diabetics and 336 control subjects revealed an ATG repeat expansion of this gene in type 2 
diabetics [148]. However, this mutation occurs at low frequency and is not closely 
associated with the development of common type 2 diabetes. Nevertheless, it may cause a 
subgroup of this polygenic disease [1, 2, 148]. Association of the single nucleotide 
polymorphisms (SNPs) rs312480, rs312486 and rs9841978 in the human CaV1.3 subunit 
gene with impaired insulin secretion and type 2 diabetes has been examined in 8,987 non-
diabetic Finnish and Swedish people and 2,830 Finnish and Swedish patients with type 2 
diabetes. It shows that the SNP rs312480 is associated with decreased mRNA expression of 
the CaV1.3 subunit gene and reduced glucose-stimulated insulin secretion and that the SNPs 
rs312486 and rs9841978 are associated with type 2 diabetes [145]. The SNP rs673391 in 
the human CaV2.3 subunit has also been revealed to be associated with type 2 diabetes and 
impaired insulin secretion and in particular reduced second-phase insulin secretion by the 
Botnia Study Group in collaboration with others [146]. A genomewide linkage analysis has 
identified a novel neonatal diabetes locus mapped to chromosome 10p12.1-p13 in a large 
consanguineous family with autosomal recessively inherited neonatal diabetes [1, 2, 151]. 
This region comprises the CaVβ2 subunit gene, which is predominantly expressed in the β 
cell, [152]. Furthermore, all affected individuals in this family showed low or even 
undetectable levels of circulating insulin indicating inadequate β cell mass and impaired 
insulin synthesis and secretion [1, 2, 151]. These findings suggest that the CaVβ2 subunit 
gene should be one of potential susceptibility genes for neonatal diabetes [1, 2, 151]. It may 
also be true for a subgroup of type 2 diabetes developed from transient neonatal diabetes. 
1.3.5.3.4 Destructive action of β cell CaV channels on β cells 
CaV channels act as a central player in control of dynamics and homeostasis of [Ca2+]i in 
the β cell [1-3]. In the context of pathology, they execute destructive action on β cells by 
mediating either deleteriously high or harmfully low Ca2+ influxes [1-3]. The former gives 
rise to Ca2+ overload and in turn triggers apoptotic and necrotic β cell death via various 
Ca2+-sensitive enzymes, e.g., calpain, calcineurin, endonucleases and transglutaminase [1-3, 
153-156]. The latter leads to Ca2+ deficiency and consequent β cell destruction through 
extinction of Ca2+-dependent enzymatic reactions critical for β cell viability [1-3]. 
Additionally, physiological Ca2+ influx through β cell CaV channels can also serve as a 
permissive condition for initiation of some apoptosis. For example, interleukin 1β loses its 
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ability to induce β cell apoptosis upon pharmacological ablation of CaV1 channels-mediated 
Ca2+ influx [2, 156]. 
The Ca2+-dependent, non-lysosomal cysteine protease calpain cleaves and activates 
caspase-12 and cyclin-dependent kinase 5 to mediate Ca2+-dependent apoptosis [2, 157, 
158]. It also stimulates calcineurin by cleaving the endogenous calcineurin inhibitor 
cain/cabin1 to provoke Ca2+-dependent apoptosis [159]. Calcineurin is also activated by 
Ca2+/calmodulin. This typical serine- and threonine-specific protein phosphatase 
dephosphorylates the pro-apoptotic protein Bad to trigger apoptotic events [2, 160]. When 
CaV channels becomes hyperactivated following PKC activation triggered by cytokine 
insult, calpain and calcineurin undergo sequential activation to execute β cell apoptosis via 
a cascade consisting of Bad, cytochrome c and caspases [155]. Ca2+-dependent 
endonucleases cleave chromosomal DNA into oligonucleosomal size fragments, a 
biochemical hallmark of apoptosis [160]. These DNA cutting enzymes undergo activation 
to evoke Ca2+-dependent β cell apoptosis when pathologically excessive Ca2+ ions flow 
through CaV1 channels into β cells [2, 154]. This is well exemplified by the fact that high 
glucose exposure induces typical Ca2+-dependent apoptosis which is mimicked by the KATP 
channel blocker tolbutamide, abolished by either the KATP channel opener diazoxide or the 
CaV1 channel blocker D-600, and prevented by the endonuclease inhibitor 
aurintricarboxylic acid [2, 154]. The Ca2+-activated transglutaminase 2 is ubiquitously 
expressed in mammalian cells including β cells where it extensively cross-links various 
cytoskeletal proteins and nucleosomal histones as the final steps of apoptosis [2, 161, 162]. 
Activation of transglutaminase 2 by lowering intracellular GTP can also initiate Ca2+-
dependent β cell apoptosis, which attenuates at low extracellular Ca2+ [2, 153, 160]. This 
suggests that this Ca2+-dependent β cell apoptosis results from CaV channel-mediated Ca2+ 
influx [2]. 
These findings pinpoint β cell CaV channels as potential therapeutic targets for the 
prevention of β cell loss during the development of diabetes. As a matter of fact, it has been 
verified that systemic application of the CaV1 channel blocker verapmil satisfactorily 
ameliorates and even prevents low-dose streptozotocin-induced progressive diabetes in 
mice through reduction of β cell apoptosis and promotion of β cell survival and function 
[163]. 
1.4 T1D SERUM-INDUCED HYPERACTIVATION OF CAV CHANNELS IN THE  
CELL 
Our group has pioneered research into T1D serum-induced hyperactivation of CaV channels 
in the pancreatic β cell and suggested that ApoCIII is likely to act as the actual factor in 
T1D serum to hyperactivate β cell CaV1 channels [5, 6]. 
1.4.1 T1D serum-induced hyperactivation of β cell CaV channels 
Our earliest observation demonstrates that T1D serum hyperactivates β cell CaV1 channels 
driving excessive unphysiological Ca2+ influx into β cells and consequent Ca2+-dependent β 
cell apoptosis [5]. In this observation, single channel analysis reveals that β cell CaV1 
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channels open more frequently following treatment with T1D serum. Correspondingly, 
whole-cell patch-clamp recordings show that a massive increase in CaV1 currents occurs in 
T1D serum-treated β cells. Consequently, such an abnormal Ca2+ influx brings about β cell 
Ca2+ overload as verified by ratiometric [Ca2+]i measurements. The Ca2+ overload 
eventually provokes the appearance of typical apoptotic DNA “ladder” in β cells. The T1D 
serum-induced β cell apoptosis no longer occurs upon pharmacological ablation of CaV1 
channels. This verifies that hyperactivated CaV channels operate as a conveyor for apoptotic 
cues from T1D serum to β cells [5]. To extend this observation, we have identified two 
obvious questions. First, do β cell CaV1 channels increase their conductivity, density or 
both in response to T1D serum exposure? Second, which CaV1 channel subtype(s) undergo 
hyperactivation when insulted with T1D serum? 
1.4.2 ApoCIII mimics the action of T1D serum on β cell CaV channels 
Our extended study reveals that significantly higher levels of ApoCIII arise in T1D sera. 
This apolipoprotein is capable of mimicking the action of T1D serum on β cell CaV 
channels. Treatment with ApoCIII dramatically elevates whole-cell CaV channel currents 
and [Ca2+]i in the β cell and evidently induces β cell apoptosis. Immunoneutralization of 
ApoCIII with anti-ApoCIII antibodies competently abrogates both T1D serum- and 
ApoCIII-induced increases in [Ca2+]i and apoptosis [6]. Unfortunately, the scope of the 
study does not cover full characterization of β cell CaV channels exposed to ApoCIII. The 
present PhD thesis sets out to mechanistically dissect the T1D serum- and ApoCIII-induced 
CaV channel hyperactivation staring with addressing the following two issues. One is which 
CaV channel type(s) are targeted by ApoCIII? The other is do β cell CaV channels increase 
their conductivity, density or both following ApoCIII treatment? 
The signaling mechanisms whereby ApoCIII hyperactivates β cell CaV channels were 
not touched in the aforementioned study [6]. Available data do not hint at direct interactions 
between ApoCIII and CaV channels. Obviously, it is important to reveal how ApoCIII 
signals to β cell CaV channels. We proposed a signaling pathway sequentially involving 
ApoCIII, SR-BI, β1 integrin, PKA/PKC/Src and CaV channels in the β cell in terms of the 
following observations. They demonstrate that SR-BI not only physically associates with 
ApoCIII in a CHO heterologous expression system but also interacts with β1 integrin in 
microglial cells [30, 164]. ApoCIII stimulates PKC through indirect interaction with β1 
integrin in monocytic cells [37]. Furthermore, β1 integrin activation can also increase CaV1 
channel activity in neurons, ventricular myocytes and vascular smooth muscle cells through 
stimulation of PKA, PKC and Src kinase [165-168]. In fact, all these components are 
expressed in β cells [2, 169-172]. Therefore, we focused on this signaling pathway. 
ApoCIII may impair β cell endocytosis to upregulate CaV channel density in the β cell 
plasma membrane. Endocytosis exquisitely internalizes membrane proteins and lipids, and 
thereby critically controlling the density of structural and functional components in the 
plasma membrane [173-175]. Mechanistically, endocytosis operates under direct control of 
a complex molecular network where the interaction of dynamin with syndapin/PACSIN 
takes center stage [174-178]. Syndapin was originally identified as a synaptic dynamin-
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associated protein in the rat brain [179]. Its mouse homolog was independently discovered 
and named PACSIN symbolizing a protein kinase C (PKC) and casein kinase 2 (CK2) 
substrate in neurons [180]. Later, this neuron-specific isoform was called syndapin 
I/PACSIN 1 (PCS1) since other isoforms, syndapin II/PACSIN 2 and syndapin III/PACSIN 
3, were detected in other tissues [176, 181-184]. β cell CaV channels critically rely on the 
endocytic machinery for their internalization to exquisitely control their density in the 
plasma membrane [173-175]. ApoCIII inhibits the endocytosis of cholesterol-rich LDLs 
[30-32]. Therefore, we have also devoted considerable efforts to investigating the possible 
involvement of PCS1-dependent endocytosis in ApoCIII-induced hyperactivation of CaV 
channels in the pancreatic β cell. 
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2 SPECIFIC AIMS 
The overall goal of this PhD work is to mechanistically dissect T1D serum-induced 
hyperactivation of CaV1 channels in the pancreatic β cell. It includes the following specific 
aims: 
1) To clarify if functional CaV1.3 channels are present in mouse islet CaV1.2-/- β cells; 
2) To determine if T1D serum affects either or both of CaV1.2 and CaV1.3 channels in 
the β cell; 
3) To verify if T1D serum alters CaV1 channel conductivity, CaV1 channel density, or 
both in the β cell plasma membrane; 
4) To electrophysiologically confirm if ApoCIII in T1D serum acts as the actual factor 
enhancing β cell CaV channel currents; 
5) To examine if ApoCIII selectively hyperactivates β cell CaV1 channels; 
6) To elucidate if ApoCIII elevates both conductivity and number of CaV1 channels in 
the β cell plasma membrane; 
7) To evaluate if ApoCIII influences β cell CaV1 channel expression; 
8) To assess if SR-BI and β1 integrin mediate ApoCIII-induced hyperactivation of β cell 
CaV1 channels; 
9) To investigate if PKA, PKC and Src kinase participate in ApoCIII-induced 
hyperactivation of β cell CaV1 channels; 
10) To characterize if PCS1-mediated endocytosis regulates the number of CaV1 
channels in the β cell plasma membrane; 
11) To explore if ApoCIII impairs PCS1-mediated endocytosis to elevate the density of 
CaV1 channels in the β cell plasma membrane. 
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3 MATERIALS AND METHODS 
3.1 ANIMALS 
Adult male and female specific pathogen-free Wistar rats and C57BL/6 mice were obtained 
from Charles River Laboratories (Sulzfeld, Germany). β Cell-specific CaV1.2 subunit-
knockout (CaV1.2-/-) mice and their corresponding heterozygous (CaV1.2+/-) control mice 
were provided by Dr. Franz Hofmann (Institut für Pharmakologie und Toxikologie, 
Technische Universität München, Germany) [60]. General CaV1.3 subunit-knockout (CaV1.3-
/-) mice and wild type control (CaV1.3+/+) mice were provided by Dr. Jörg Striessnig (Institute 
of Pharmacy, Pharmacology and Toxicology, University of Innsbruck, Austria) [185]. These 
knockout mouse lines were created on the C57BL/6 background. The animals were 
maintained on a regular light-dark cycle (lights on at 07.00 h and off at 19.00 h) in 
temperature and humidity-controlled rooms. They had free access to food pellets and tap 
water. All animal experiments were conducted according to the guidelines of the Animal 
Experiment Ethics Committee at Karolinska Institutet. 
3.2 ISOLATION AND CULTIVATION OF ISLETS OF LANGERHANS 
Rat islets of Langerhans were isolated using the in situ ductal perfusion technique. Briefly, 
rats were anesthetized with CO2 and then killed by decapitation. The rat abdominal cavity 
was opened to expose the pancreas. About 15 ml of collagenase A solution (1.2 mg/ml; 
Roche, Basel, Switzerland) was injected into the pancreas through the common bile duct. The 
distended pancreas was quickly dissected, rinsed with Hank’s buffered salt solution (HBSS) 
(Invitrogen, Carlsbad, CA, USA), placed into the collagenase A solution and digested under 
mild shaking for about 20 min at 37°C. The digestion was stopped by addition of HBSS. The 
digested pancreas was passed through 14 gauge needle several times. Dissociated islets were 
hand-picked up under a microscope. 
Mouse islets of Langerhans were isolated using the standard chopped tissue technique. In 
short, the mice were killed by cervical dislocation. The pancreas was quickly dissected and 
cut into small pieces. Subsequently, the cut pancreatic tissue was digested with collagenase A 
(Roche) under vigorous shaking for 10-12 min at 37°C. The digested pancreatic tissue was 
rinsed twice with a solution containing 125 mM NaCl, 5.9 mM KCl, 1.28 mM CaCl2, 1.2 
mM MgCl2, 10 mM HEPES, 0.1 % bovine albumin and 3 mM glucose, pH7.4. Dissociated 
islets were hand-picked up under a microscope. 
Obtained islets were subjected to either cultivation in RPMI 1640 medium supplemented 
with 10 % fetal bovine serum, 2 mM L-glutamine and 100 U/100 µg/ml 
penicillin/streptomycin (Invitrogen) at 37°C in a humidified 5 % CO2 incubator or 
dissociation into single islet cells. 
3.3 CELL CULTURE 
Islet cell culture was performed according to the following procedures. Rat and mouse islets 
were dispersed into single islet cells in a Ca2+-free medium containing 125 mM NaCl, 5.9 
mM KCl, 2 mM EGTA, 25 mM HEPES and 1 % bovine serum albumin, pH 7.4. The 
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dispersed cells were incubated in RPMI 1640 medium supplemented with 10 % fetal bovine 
serum, 2 mM L-glutamine and 100 U/100 µg/ml penicillin/streptomycin (Invitrogen) and 
maintained at 37°C in a humidified 5 % CO2 incubator for 2-4 days. 
HIT-T15 and RINm5F cells were cultured in RPMI 1640 medium supplemented with 10 
% fetal bovine serum, 2 mM L-glutamine, and 100 U/100 µg/ml penicillin/streptomycin 
(Invitrogen). INS-1 cells were cultivated in RPMI 1640 medium containing the following 
additives: 10 % fetal bovine serum, 2 mM L-glutamine, 100 U/100 µg/ml 
penicillin/streptomycin, 10 mM HEPES, 1 mM sodium pyruvate and 50 μM β-
mercaptoethanol (Invitrogen). MIN6-m9 cells were grown in DMEM medium with the 
following supplements: 10 % fetal bovine serum, 100 U/100 µg/ml penicillin/streptomycin, 
11 mM glucose and 0.0005 % β-mercaptoethanol (Invitrogen). The cells were maintained at 
37°C in a humidified 5 % CO2 incubator and grown to approximately 70 % confluency 
before use. 
3.4 PREPARATION OF SERA FROM HEALTHY HUMAN SUBJECTS AND 
PATIENTS WITH T1D 
Blood samples were collected into test tubes from healthy blood donors and T1D patients, 
respectively. The samples were centrifuged and the resultant sera were aspirated into 
Eppendorf tubes. The collected sera were heat-inactivated at 56°C for 30 min and stored at -
70°C until use. The T1D patients were newly diagnosed and only treated with exogenous 
insulin when their sera were collected. They had neither ketoacidosis nor severe 
hyperglycemia. The sodium, potassium and urea values of the collected T1D sera were within 
the normal range. 
3.5 TREATMENTS 
Islet cells from CaV1.2-/- and CaV1.2+/- mice as well as CaV1.3-/- and CaV1.3+/+ mice were 
incubated overnight in RPMI 1640 medium containing 10 % healthy human serum, 10 % 
T1D patient serum or 10 % T1D patient serum plus rabbit polyclonal anti-ApoCIII antibodies 
(100 μg/ml, Academy BioMedical, Houston, TX, USA). Mouse islet CaV1.2-/- β cells were 
acutely exposed to the CaV1 channel blocker nimodipine (10 μM, Calbiochem, La Jolla, CA, 
USA). RINm5F cells were subjected to overnight treatment with ApoCIII, the PKA inhibitors 
H-89 (Calbiochem) and myristoylated PKI (14-22) (PKI, Sigma-Aldrich, St. Louis, MO, 
USA), the PKC inhibitor calphostin C (Calbiochem), the Src kinase inhibitor PP2 
(Calbiochem) and the CaV1 channel blocker nimodipine (Calbiochem) in RPMI 1640 
medium at final concentrations of 20 μg/ml, 0.5 μM, 1 μM, 0.1 μM, 0.1 μM and 5 μM, 
respectively. Mouse β cells were treated with ApoCIII (20 μg/ml) overnight. ApoCIII was 
dissolved in 0.1 % triflouroacetic acid (TFA) to make a stock solution of 1 mg/ml, PKI was 
dissolved in water to prepare a stock solution of 0.5 mM, whereas H-89, calphostin C, PP2 
and nimodipine were dissolved in dimethyl sulfoxide (DMSO) to make stock solutions of 5 
mM, 1 mM, 1 mM and 10 mM, respectively. 0.002 % TFA and/or 0.03 % DMSO were used 
as corresponding vehicle controls. RINm5F cells were stimulated for 5 min with 10 mM 
glyceraldehyde plus 2.8 mM glucose or 30 mM KCl to induce regulated endocytosis. 
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3.6 siRNA SILENCING 
21-mer siRNAs targeting the rat β1 integrin (β1 integrin siRNA1, ID127971 and β1 integrin 
siRNA2, ID127972), rat SR-BI (SR-BI siRNA, ID128929) as well as rat PCS1 (PCS1 
siRNA1, ID S132057 and PCS1 siRNA2, ID S132056) were designed and chemically 
synthesized by Applied Biosystems/Ambion (Austin, TX, USA). Their sequences were 
confirmed by BLAST searches to ensure their specificity. Silencer® Select Negative Control 
siRNA (4390843) (NC siRNA), not targeting any gene product, and Silencer® Select 
GAPDH Positive Control siRNA (4390849), efficiently silencing GAPDH in human, mouse, 
and rat cells, were purchased from Applied Biosystems/Ambion (Austin, TX, USA). 
RINm5F cells were transfected with the aforementioned siRNAs using Lipofectamine® 
RNAiMAX (Invitrogen). In brief, NC siRNA, GAPDH siRNA, β1 integrin siRNA1, β1 
integrin siRNA2, SR-BI siRNA, PCS1 siRNA1 or PCS1 siRNA2 was mixed with 
Lipofectamine® RNAiMAX followed by 20-min incubation at room temperature. Thereafter, 
cells were added to the siRNA/Lipofectamine® RNAiMAX mixtures followed by gentle 
agitation and kept at 37°C in a humidified 5 % CO2 incubator. After 72 h, the transfected 
cells were grown to about 70 % confluency and knockdown efficiency was evaluated by 
immunoblot assay. 
3.7 SEMIQUANTITATIVE RT-PCR 
Total RNA was extracted from RINm5F cells using the RNeasy Micro Kit (Qiagen, Valencia, 
CA, USA). Oligonucleotide primer pairs for RT-PCR amplification were synthesized by 
Sigma-Aldrich. The SR-BI primer pair included the forward primer 5’-
CAAGAAGCCAAGCTGTAGGG-3’ and the reverse primer 5’-
CCCAACAGGCTCTACTCAGC-3’. The GAPDH primer pair consisted of the forward 
primer 5’-TAGACAAGATGGTGAAGG-3’ and the reverse primer 5’-
TCCTTGGAGGCCATGTAG-3’. 500 ng of total RNA was reverse transcribed using 
SuperScript® II Reverse Transcriptase (Invitrogen) and Oligo(dT)12-18 Primer (Invitrogen). 
Polymerase chain reaction was performed using the Platinum® Taq DNA Polymerase 
(Invitrogen). The reaction underwent 90 seconds at 94°C for completely denaturing templates 
and activating the Taq DNA Polymerase, followed by 29 cycles of denaturing at 94°C for 30 
seconds, annealing at 55°C for 30 seconds and extension at 72°C for 30 seconds, and ending 
with a final extension at 72°C for 5 min. The amplified PCR products were analyzed by 2 % 
agarose gel electrophoresis and ethidium bromide staining. 
3.8 SINGLE CELL RT-PCR 
The entire islet cell was collected with a glass pipette after a patch-clamp recording and 
stored in a PCR tube with 10 µl 1x Taq DNA polymerase reaction buffer containing MgCl2 
(Promega, Madison, WI, USA) at -70°C for later use. Expression of insulin mRNA in 
collected single cells was determined using the QIAGEN OneStep RT-PCR Kit (Valencia, 
CA, USA) according to the manufacturer’s instructions. The RNasin Plus RNase Inhibitor 
(Promega) was used to avoid damaging mRNA. The insulin primer pair for RT-PCR analysis 
was synthesized by Sigma-Aldrich. It comprised the forward primer 5’-
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CAGCAAGCAGGTCATTGTTT-3’ and the reverse primer 5’-
CAGTAGTTCTCCAGCTGGTAGA-3’. These primers were added at a final concentration 
of 0.6 µM to the reaction mix. The reaction was amplified for 35 cycles of 94°C for 1 min, 
62°C for 1 min and 72°C for 1 min. The amplified PCR products were resolved by 2 % 
agarose gel electrophoresis and visualized by ethidium bromide staining. 
3.9 SDS-PAGE AND IMMUNOBLOT ANALYSIS 
Mouse islets and exocrine tissue were isolated using the standard chopped tissue technique. 
The pancreas, brain, heart, kidney, liver, lung, muscle and spleen were quickly dissected out 
from cervically dislocated mice. The harvested tissues as well as insulin-secreting HIT-T15, 
INS-1, MIN6-m9 and RINm5F cells were homogenized on ice in 250 μl of a homogenization 
buffer (pH 7.4) consisting of 20 mM HEPES, 1 mM MgCl2, 2 mM EDTA, 250 mM sucrose, 
1 mM PMSF and a protease inhibitor cocktail (Roche). The resultant homogenates were 
pelleted at 800 x g for 10 min to remove nuclei, unbroken cells and debris. The protein 
concentration of the pelleted homogenates was measured with Bio-Rad protein assay reagent 
(Bio-Rad, Hercules, CA, USA). These homogenate samples were then denatured by heating 
at 96ºC for 3 min in SDS sample buffer and subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblot analysis. In brief, 
45-180 µg proteins were separated in discontinuous gels consisting of a 4 % acrylamide 
stacking gel (pH 6.8) and a 8 % acrylamide separating gel (pH 8.8). The separated proteins 
were then electrophoretically transferred to hydrophobic polyvinylidene difluoride membrane 
(Hybond-P; Amersham, Buckinghamshire, UK). The blots were blocked by incubation for 1 
h with 5 % non-fat milk powder in a washing buffer consisting of 50 mM 
tris(hydroxymethyl)aminomethane, 150 mM NaCl and 0.05 % Tween 20 (pH 7.5). The 
blocked blots were incubated overnight at 4ºC with affinity-purified rabbit polyclonal 
antibodies against β1 integrin (1:500; Millipore, Billerica, MA, USA), CaV1.2 (1:200), 
CaV1.3 (1:200), SR-BI (1:2500; Novus, Cambridge, UK) and PCS1 (1:1000), respectively, 
and for 1 h at room temperature with mouse monoclonal antibody to GAPDH (1:4000; 
Applied Biosystems/Ambion). Subsequently, the blots were rinsed with the washing buffer 
and incubated with the secondary antibodies (either horseradish peroxidase-conjugated goat 
anti-rabbit IgG or horseradish peroxidase-conjugated goat anti-mouse IgG; 1:50,000; Bio-
Rad) at room temperature for 45 min. The immunoreactive bands were visualized with the 
ECL plus Western blotting detection system (GE Healthcare, Uppsala, Sweden). Anti-CaV1.2 
and anti-CaV1.3 antibodies were provided by Dr. William A. Catterall (Department of 
Pharmacology, University of Washington, WA, USA). Anti-PCS1 antibodies were provided 
by Dr. Britta Qualmann (Institute for Biochemistry I, Friedrich Schiller University Jena, Jena, 
Germany). 
3.10 IMMUNOCYTOCHEMISTRY 
Isolated rat and mouse islets as well as cultured rat and mouse islet cells were subjected to 
double immunolabeling. Isolated islets were fixed with 4 % paraformaldehyde for 90 min. 
Cultured rat and mouse islet cells on glass coverslips were fixed in 2 % paraformaldehyde for 
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30 min. Both the fixed islets and cultured cells were incubated with 5 % normal goat serum 
(Sigma-Aldrich) for 1 h to block nonspecific staining. Subsequently, the specimens were 
double-labeled with rabbit polyclonal antibodies to PCS1 (1:200) and guinea pig polyclonal 
antibodies to insulin (1:200; Dako, Glostrup, Danmark) at 4°C overnight. They were then 
incubated with goat anti-rabbit or anti-guinea pig IgG coupled to Alexa 488 or Alexa 633 
(1:200; Molecular Probes, Eugene, OR, USA) for 20 min at room temperature. Negative 
controls included omission of the primary antibodies, incubation with nonimmune IgG from 
corresponding species and preabsorption of the anti-insulin (1:200) with bovine insulin (1000 
µg/ml). The specimens were mounted in ProLong Gold Antifade (Molecular Probes), 
coverslipped and sealed with nail polish. 
3.11 CONFOCAL MICROSCOPY AND DECONVOLUTION ANALYSIS 
Double immunofluorescence-labeled islets and islet cells were visualized with a Leica TCS-
SP5II-AOBS confocal laser-scanner equipped with a 405 nm Diode laser, an Argon laser 
(458, 476, 488, 496, 514 nm lines), a 561 nm DPSS lasers, a 594 nm HeNe laser and a 633 
nm HeNe laser and connected to a Leica DM6000 CFS microscope (Leica Microsystems 
Heidelberg GmbH, Mannheim, Germany). Alexa 488 linked to goat anti-rabbit and Alexa 
633 conjugated to goat anti-guinea pig IgG were excited by 488 and 633 nm laser lines, 
respectively, and the resultant emissions were collected at 499-537 and 648-734 nm, 
respectively. Optical sections were acquired using Leica HCX IRAPO L 25x/0.95 water and 
HCX PL APO 100x/1.44 oil objectives. The confocal images were processed and 
deconvoluted with Huygens Essential (Scientific Volume Imaging, Hilversum, Netherlands). 
Live-cell confocal imaging of FM1-43 was conducted on RINm5F cells. The cells were 
incubated for 30 min with RPMI 1640 medium containing no glucose and then for 10 min 
with extracellular solution consisting of 135 mM NaCl, 3.6 mM KCl, 5 mM NaHCO3, 0.5 
mM NaH2PO4, 0.5 mM MgCl2, 1.5 mM CaCl2, 10 HEPES and 0.1 % bovine serum albumin. 
Subsequent addition of FM1-43 (Molecular Probes) at a concentration of 5 μM proceeded. 
Some cells were maintained in the extracellular solution for further 60 min for constitutive 
endocytosis assay and other cells were stimulated for 5 min with 10 mM glyceraldehyde plus 
2.8 mM glucose for regulated endocytosis measurements. FM1-43 accumulation in the cells 
was visualized with a Leica TCS-SP2 confocal laser-scanner connected to a Leica DMIRBE 
microscope (Leica). FM1-43 was excited by a 488 nm laser line and the resultant emission 
was collected using a Leica PL APO 100x/1.40 oil objective at 540-650 nm. FM1-43 
fluorescence images were acquired at 37ºC. Quantification of intracellular FM1-43 
fluorescence intensity was done using Leica Confocal Software (Leica). 
3.12 ELECTROPHYSIOLOGY 
RINm5F cells and mouse islet cells from CaV1.2-/- and CaV1.2+/- mice as well as CaV1.3-/- and 
CaV1.3+/+ mice were subjected to different patch-clamp measurements. The cell-attached, 
conventional whole-cell and perforated whole-cell configurations of the patch-clamp 
technique were employed to register single CaV channel currents and whole-cell CaV channel 
currents, respectively. Recording electrodes were pulled from borosilicate glass capillaries 
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(Hilgenberg, Malsfeld, Germany), fire-polished on a horizontal programmable puller (DMZ 
Universal Puller, Zeitz-Instrumente, Augsburg, Germany) and then coated with Sylgard close 
to their tips. The electrode resistance ranged between 4 and 6 MΩ when electrodes were filled 
with electrode solutions and immersed in bath solutions. The electrode offset potential was 
corrected in bath solutions prior to gigaseal formation. 
Cell-attached single CaV channel current recordings were made with an Axopatch 200B 
amplifier together with the software program pCLAMP 10 (Molecular Devices, Foster City, 
CA, USA). Electrodes were filled with a solution containing 110 mM BaCl2, 10 mM 
tetraethylammonium chloride and 5 mM HEPES-Ba(OH)2 (pH 7.4). Ba2+ was used as the 
charge carrier. A depolarizing external recording solution, containing 125 mM KCl, 30 mM 
KOH, 10 mM EGTA, 2 mM CaCl2, 1 mM MgCl2, 5 mM HEPES-KOH (pH 7.15), was used 
to bring the intracellular potential to ~0 mV. Voltage pulses (200 ms) were applied at a 
frequency of 0.5 Hz to depolarize cells from a holding potential of -70 mV to a membrane 
potential of 0 mV. Resulting currents were filtered at 1 kHz and digitized at 5 kHz. All 
recordings were made at room temperature (about 22°C). Acquisition and analysis of data 
were done using the software program pCLAMP10 (Molecular Devices). 
Whole-cell CaV channel current data were acquired with an Axopatch 200B amplifier 
together with the software program pCLAMP 10 (Molecular Devices) or an EPC-9 patch-
clamp amplifier together with the software program PatchMaster (HEKA Elektronik, 
Lambrecht/Pfalz, Germany). For conventional whole-cell recordings, electrodes were filled 
with a solution consisting of 150 mM N-methyl-D-glucamine, 125 mM HCl, 10 mM EGTA, 
1.2 mM MgCl2, 3 mM MgATP, and 5 mM HEPES (pH 7.15). In perforated whole-cell patch-
clamp experiments, the electrode solution contained 76 mM Cs2SO4, 1 mM MgCl2, 10 mM 
KCl, 10 mM NaCl, and 5 mM HEPES (pH 7.35), as well as amphotericin B (0.24 mg/ml) to 
permeabilize the plasma membrane and allow low-resistance electrical access without 
breaking the patch. Cells used for both conventional and perforated whole-cell recordings 
were bathed in a solution containing 138 mM NaCl, 10 mM tetraethylammonium chloride, 10 
mM CaCl2, 5.6 mM KCl, 1.2 mM MgCl2, 5 mM HEPES and 3 mM glucose (pH 7.4). After 
obtaining a seal, the holding potential was set to -70 mV during the course of an experiment. 
Depolarizing voltage pulses (100 ms) were made from a holding potential of -70 mV to 
several test potentials from -60 to 50 mV in 10 mV increments at 0.5 Hz. Resulting currents 
were filtered at 1 kHz and digitized at 5 kHz. All recordings were made at room temperature 
(about 22°C). Data analysis were done using pCLAMP10 (Molecular Devices) or FitMaster 
(HEKA). The amplitude of whole-cell currents was normalized to cell capacitance. To ensure 
exclusion of rapid transient Na+ currents appearing at the initial period of depolarization 
during whole-cell CaV channel current recordings in RINm5F cells, we measured peak 
whole-cell CaV channel currents within a time window from 30 ms to 100 ms after start of 
depolarization. 
3.13 STATISTICAL ANALYSIS 
All data are presented as mean ± SEM. The non-parametric Kruskal-Wallis test or one-way 
ANOVA followed by least significant difference (LSD) test was used to compare multiple 
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groups. The non-parametric Mann-Whitney U test or unpaired Student’s t test was employed 
to compare two groups. The significance level was set to 0.05. 
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4 RESULTS AND DISCUSSION 
4.1 FUNCTIONAL CAV1.3 CHANNELS ARE PRESENT IN A SUBGROUP OF 
MOUSE ISLET CAV1.2-/-  CELLS (PAPER I) 
CaV1.3 channels are expressed far more richly than CaV1.2 channels in human β cells [59, 
145, 186]. CaV1.3 channel polymorphisms are associated with diabetes [145, 148]. However, 
it still remains elusive whether functional CaV1.3 channels reside in mouse pancreatic β cells 
[1-3]. In the present PhD work, we examined the presence of functional CaV1.3 channels in 
mouse islet CaV1.2-/- β cells by combining whole-cell patch-clamp analysis and single cell 
RT-PCR assay [187]. The CaV1.3 subunit-expressing cells possessed larger capacitance (> 7 
pF) and typical CaV1 currents without superimposed voltage-gated Na+ currents (Fig. 1a in 
Paper I). Importantly, they expressed insulin mRNA (Fig. 1b in Paper I). These 
electrophysiological criteria and molecular evidence ensure their β cell identity. Among 15 
examined cells, 3 cells exhibited DHP-sensitive CaV1 currents that were blocked by 
nimodipine (Fig. 1a in Paper I). These data reveal that functional CaV1.3 channels are present 
in 20 % mouse islet CaV1.2-/- β cells [187]. Thus, the CaV1.2-/- mouse provides a convenient 
small animal model for understanding how T1D serum attacks β cells through CaV1.3 
channels. 
There has been considerable debate concerning the presence of functional CaV1.3 channels 
in the mouse islet β cell due to technical limitations [1, 2, 60, 70, 121, 188, 189]. Indeed, 
CaV1.3 channels differ appreciably from CaV1.2 channels in activation threshold and DHP 
sensitivity when heterologously expressed in Xenopus oocytes or mammalian cells [190, 
191]. However, these electrophysiological and pharmacological differences are too small to 
be used for reliable discrimination between native CaV1.2 and CaV1.3 channels in islet β 
cells. Therefore, the presence and function of CaV1.3 channels in the mouse islet β cell 
remain controversial [1, 2]. The β cell-specific CaV1.2 subunit knockout causes a significant 
reduction in CaV channel currents and insensitivity of CaV channels to isradipine (2 µM) and 
Bay K8644 (1 µM) [60]. Genetic ablation of the DHP-sensitivity of CaV1.2 subunits renders 
CaV channel currents insensitive to isradipine (2 µM) and Bay K8644 (2 µM) in mouse islet β 
cells [188]. Hence, these results speak in favor of that only CaV1.2 subunits conduct CaV1 
currents in mouse islet β cells. 
However, a series of observations argue against the conclusion that only CaV1.2 subunits 
conduct CaV1 currents in mouse islet β cells [1, 2, 70, 121, 189]. The CaV1.3 subunit gene is 
more than 155 kb long and contains 49 exons. This multi-exon gene can undergo complex 
alternative splicing to produce numerous splice variants of the CaV1.3 subunit [192, 193]. 
The distinct splice variants of CaV1.3 channels possess different sensitivities to DHPs [190, 
194]. This is explicitly exemplified in mouse hair cells where an isoform of CaV1.3 channels 
displays a rather low sensitivity to various CaV1 channel blockers [194]. Nifedipine at 10 µM 
blocks about 40 % of the Ca2+ current through this isoform. In striking contrast, nifedipine at 
100 nM can completely ablate CaV1.2-mediated Ca2+ currents [194]. Furthermore, CaV1.3 
subunit mRNAs and proteins have convincingly been detected in mouse islet β cells [70, 121, 
189]. Genetic ablation of CaV1.3 subunits abrogates basal insulin secretion from mouse islets 
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[70]. Importantly, we now verify that a proportion of mouse islet CaV1.2-/- β cells express 
functional CaV1.3 channels [187]. These observations support the existence of functional 
CaV1.3 channels in mouse islet β cells. 
4.2 T1D SERUM HYPERACTIVATES BOTH CAV1.2 AND CAV1.3 CHANNELS 
BY INCREASING THEIR CONDUCTIVITY AND NUMBER IN THE β CELL 
PLASMA MEMBRANE (PAPER I) 
To characterize influences of T1D serum on β cell CaV1.3 channel behaviors, we performed 
cell-attached single-channel recordings in mouse islet CaV1.2+/- and CaV1.2-/- β cells [187]. In 
comparison to healthy serum, T1D serum not only made CaV1 channels spend more time in 
their open state, but also elevated the number of functional CaV1 channels, reflected by more 
unitary conductance levels (more layers of unitary Ba2+ currents) in both CaV1.2+/- and 
CaV1.2-/- β cells (Fig. 2a and c in Paper I). There are significant increase in the number, open 
probability and mean open time of CaV1 channels and significant decrease in the mean closed 
time of these channels in both CaV1.2+/- and CaV1.2-/- β cells exposed to T1D serum (Fig. 2b 
and d in Paper I). 
Next, we characterized T1D serum-induced alterations of β cell CaV1.2 channels in mouse 
islet CaV1.3+/+ and CaV1.3-/- β cells by using perforated whole-cell and cell-attached single-
channel patch-clamp techniques [187]. Whole-cell patch-clamp measurements revealed that 
T1D serum prominently increased whole-cell CaV channel currents in CaV1.3+/+ and CaV1.3-/- 
cells leading to significant elevation of whole-cell CaV channel current density in comparison 
to healthy serum (Fig. 3 in Paper I). Cell-attached single-channel analysis showed that both 
CaV1.3+/+ and CaV1.3-/- cells subjected to T1D treatment displayed more single CaV1 
channels, manifested by more layers of unitary Ba2+ currents, and stayed open longer in 
comparison to those exposed to healthy serum (Fig. 4a and c in Paper I). The number, open 
probability and mean open time of single CaV1 channels following T1D serum treatment 
were significantly greater than those exposed to healthy serum. The mean closed time of 
single CaV1 channels exposed to T1D serum incubation was significantly shorter than that 
subjected to healthy serum treatment (Fig. 4b and d in Paper I). 
A prerequisite for curing the polygenic metabolic disorder diabetes is a clear identification 
of individual genes involved [195-199]. We have previously revealed that hyperactivated β 
cell CaV1 channels by T1D serum mediate pathologically-exaggerated Ca2+ influx into 
pancreatic β cells leading to β cell apoptosis [5]. Two molecular subtypes of CaV1 channels, 
CaV1.2 and CaV1.3, are present in β cells [1-4]. It is important to know if T1D serum targets 
either or both of these two CaV1 subtypes in terms of prevention of Ca2+-dependent β cell 
apoptosis. To gain such knowledge, we have carried out the present study. It turns out that 
T1D serum drives hyperactivation of both of these two CaV1 subtypes [187]. This finding 
pinpoints that CaV1.2 and CaV1.3 channels in the β cell are vulnerable to the attack of T1D 
serum, that their hyperactivation most likely underlies the molecular pathogenesis of T1D and 
that both CaV1.2 and CaV1.3 channels in the β cell should be considered to be target 
molecules for preventing and treating diabetes. 
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In our previous work, we revealed that T1D serum significantly elevates the amplitude of 
whole-cell and average unitary CaV1 currents in the β cell [5]. This could result from the 
enriched density and/or increased conductivity of these channels in the β cell plasma 
membrane. To determine which scenario occurred, the present work has now carefully 
characterized how T1D serum influences CaV1 channel behaviors. The obtained data on the 
biophysical properties of single CaV1 channels in CaV1.2+/-, CaV1.2-/-, CaV1.3+/+ and CaV1.3-/- 
β cells exposed to T1D serum enable us to mechanistically interpret T1D serum-induced 
hyperactivation of β cell CaV1 channels [187]. The CaV1 channel hyperactivation happens 
due to both the increased conductivity and elevated number of functional CaV1 channels in 
the recorded area of the β cell plasma membrane. The former is exhibited as an increased 
open probability attributed to the prolonged mean open time and shortened mean closed time. 
The latter is manifested as more levels of single CaV1 channel conductance [187]. These 
findings suggest that this T1D serum-induced pathological event likely involves multiple 
mechanisms to which attention should be drawn for effective intervention. 
4.3 APOCIII IN T1D SERUM ACTS AS THE ACTUAL FACTOR ENHANCING β 
CELL CAV CHANNEL CURRENTS 
To electrophysiologically verify if elevated ApoCIII in T1D serum enhances CaV1 channel 
currents in the β cell, we examined the effect of immunoneutralization of ApoCIII with anti-
ApoCIII antibodies on T1D serum-induced enhancement of CaV channel currents in mouse 
islet β cells by using perforated whole-cell patch-clamp analysis. It turned out that whole-cell 
CaV channel currents were larger in T1D serum-treated cells than in cells exposed to healthy 
serum (Fig. 1A). Importantly, whole-cell CaV channel currents in cells exposed to T1D serum 
pre-absorbed with anti-ApoCIII antibodies were similar to those appearing in healthy serum-
treated cells (Fig. 1A). Whole-cell CaV channel current densities were significantly higher in 
T1D serum group than in healthy serum group (Fig. 1B). However, whole-cell CaV channel 
current densities measured in cells incubated with T1D serum pre-absorbed with anti-
ApoCIII antibodies were not statistically different from those visualized in healthy serum-
treated cells (Fig. 1B). It is clear that ApoCIII-depleted T1D serum could no longer enhance 
CaV channel currents in the β cell. 
Indeed, our previous studies demonstrate that T1D serum contains elevated ApoCIII. 
Incubation with T1D serum significantly enhances [Ca2+]i response to K+ depolarization and 
thereby promotes β cell death [5, 6]. Pre-absorption of T1D serum with anti-ApoCIII 
antibodies efficiently prevents the enhanced [Ca2+]i response and β cell death [6]. Exposure to 
either T1D serum or ApoCIII hyperactivates β cell CaV channels [5, 6]. These documented 
results indicate that ApoCIII in T1D serum is most likely to act as the actual player in 
hyperactivation of β cell CaV channels [5, 6, 200]. However, these findings did not 
electrophysiologically verify this indication [5, 6, 200]. We now show for the first time that 
ApoCIII-depleted T1D serum is incapable of enhancing CaV channel currents in the β cell. 
This confirms that ApoCIII indeed is the molecular entity in T1D serum responsible for 
hyperactivation of β cell CaV channels. 
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4.4 APOCIII SELECTIVELY HYPERACTIVATES β CELL CAV1 CHANNELS 
(PAPER II) 
To clarify what type of β cell CaV channels was altered in response to ApoCIII exposure, we 
selected RINm5F cells, which harbor the richest types of CaV channels among all available β 
cell types, for whole-cell patch-clamp analysis in combination with pharmacological 
discrimination [1-3, 200]. The obtained data show that ApoCIII in the absence of the CaV1 
channel blocker nimodipine markedly increased whole-cell CaV channel currents in 
comparison to vehicle solution (Fig. 2a in Paper II), whereas this apolipoprotein could no 
longer produce such an effect in nimodipine-pretreated cells (Fig. 2c in Paper II). Whole-cell 
CaV channel current densities were significantly higher in the ApoCIII group than in the 
control group in the absence of nimodipine (Fig. 2b in Paper II) and very similar in the 
presence of nimodipine (Fig. 2d in Paper II). These data verify that ApoCIII selectively acts 
on β cell CaV1 channels [200]. These findings further confirm that the β cell CaV1 channel 
can be a target molecule for prevention of Ca2+-dependent β cell destruction induced by the 
diabetogenic serum factor ApoCIII. 
4.5 APOCIII ELEVATES BOTH THE CONDUCTIVITY AND NUMBER OF CAV1 
CHANNELS IN THE β CELL PLASMA MEMBRANE (PAPER II) 
To determine whether the density and/or conductivity of β cell CaV channels changed in 
response to ApoCIII treatment, we analyzed unitary CaV1 channel currents, characterized by 
Figure 1. Immunoneutralization of 
ApoCIII blocks T1D serum-induced 
enhancement of CaV channel currents in 
the β cell. A: Sample whole-cell CaV 
channel current traces registered in 
mouse islet β cells following incubation 
with healthy serum (upper panel, cell 
capacitance: 5.22 pF), T1D serum 
(middle panel, cell capacitance: 5.29 pF) 
and T1D serum preabsorbed with anti-
ApoCIII antibodies (lower panel, cell 
capacitance: 5.46 pF), respectively. B: 
CaV channel current density-voltage 
relationships in cells exposed to healthy 
serum (open circles, n = 32), T1D serum 
(filled circles, n = 32) or T1D serum 
preabsorbed with anti-ApoCIII 
antibodies (filled triangles, n = 32). *P < 
0.05 and **P < 0.01 versus healthy 
serum. +P < 0.05 and ++P < 0.01 versus 
T1D serum plus anti-ApoCIII antibodies. 
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a large unitary Ba2+ conductance with long-lasting openings, in mouse islet β cells and 
insulin-secrecting RINm5F cells following ApoCIII incubation (Fig. 1 in Paper II) [200]. We 
visualized that plasma membrane patches of ApoCIII-incubated cells accommodated more 
CaV1 channels than those of vehicle-treated cells (Fig. 1a and c in Paper II). CaV1 channels 
exposed to ApoCIII opened more frequently than those bathed in vehicle solution (Fig. 1a 
and c in Paper II). ApoCIII incubation significantly increased channel number, elevated open 
probability, prolonged mean open time and shortened mean closed time of CaV1 channels in 
comparison to exposure to control vehicle (Fig. 1b and d in Paper II). Apparently, both 
conductivity and number of β cell CaV1 channels undergo elevation in response to ApoCIII 
treatment [200]. We now reveal that ApoCIII treatment boosts both the density and 
conductivity of β cell CaV1 channels [200]. The aforementioned results demonstrate that 
ApoCIII indeed is the molecular entity in T1D serum responsible for selective 
hyperactivation of β cell CaV1 channels and that such hyperactivation occurs due to both the 
increased conductivity and elevated number of these channels in the plasma membrane [200]. 
4.6 APOCIII DOES NOT INFLUENCE β CELL CAV1 CHANNEL EXPRESSION 
(PAPER II) 
Appearance of ApoCIII-induced hyperactivation of β cell CaV channels requires overnight 
incubation. Hence, the effect might be attributed to an increase in CaV channel expression. To 
clarify such a possibility, we quantified β cell CaV1 channel expression in RINm5F cells 
following ApoCIII incubation [200]. Immunoblot analysis revealed that control and ApoCIII-
treated samples gave similar intensities of CaV1.2, CaV1.3 and GAPDH immunoreactivities 
(Fig. 6a in Paper II). There was no significant difference in the relative abundance of CaV1.2 
and CaV1.3 subunits in RINm5F cell homogenates subjected to ApoCIII incubation in 
comparison to vehicle incubation (Fig. 6b in Paper II). The data firmly exclude the possibility 
that ApoCIII elevates β cell CaV1 channel expression [200]. 
4.7 APOCIII HYPERACTIVATES β CELL CAV CHANNELS THROUGH SR-BI 
AND β1 INTEGRIN (PAPER II) 
Available evidence that β1 integrin signals not only downstream of ApoCIII but also 
upstream of PKA, PKC and Src kinase to upregulate CaV channels in other cell types made us 
postulate the possibility that β1 integrin may mediate ApoCIII-induced hyperactivation of β 
cell CaV channels [37, 165-168]. We tested this postulation by implementing RNA 
interference in combination with whole-cell CaV channel current analysis in RINm5F cells 
[200]. The obtained results show that transfection with two β1 integrin siRNAs significantly 
reduced β1 integrin protein expression (Fig. 7a and b in Paper II). Importantly, β1 integrin 
siRNA pretransfection efficiently counteracted ApoCIII-induced hyperactivation of β cell 
CaV channels (Fig. 7c and d in Paper II). Whole-cell CaV channel currents in β1 integrin 
siRNA-pretransfected cells incubated with ApoCIII (β1 integrin siRNA/ApoCIII) markedly 
decreased in comparison to those in NC siRNA-pretransfected cells exposed to ApoCIII (NC 
siRNA/apoCIII), but resembled those in three sets of control cells (Fig. 7c in Paper II). These 
control treatments include control vehicle incubation following mock (NO siRNA/Control), 
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NC siRNA (NC siRNA/Control) and β1 integrin siRNA pretransfection (β1 integrin 
siRNA/Control), respectively (Fig. 7c in Paper II). CaV channel current densities were 
significantly smaller in β1 integrin siRNA/ApoCIII group than in NC siRNA/apoCIII group 
(Fig. 7d in Paper II). The former manifested similar CaV channel current density, but the latter 
showed greater CaV channel current density as compared to NO siRNA/Control, NC 
siRNA/Control or β1 integrin siRNA/Control groups (Fig. 7d in Paper II). It is known that 
ApoCIII activates β1 integrin to promote PKC-mediated monocyte adhesion [37] and that β1 
integrin activation stimulates PKA, PKC, Src kinase resulting in up-regulation of CaV 
channels in neurons, cardiomyocyte and vascular smooth muscle cells [165-168]. In line with 
these findings, our results clearly verify that β1 integrin conveys signals from ApoCIII to β 
cell CaV1 channels to mediate ApoCIII-induced hyperactivation of β cell CaV channels [200]. 
Existing documents illustrate no direct interaction of ApoCIII with β1 integrin [37, 39] 
and suggest that SR-BI should be a possible molecular bridge between ApoCIII and β1 
integrin since this receptor physically associates with ApoCIII and interacts with β1 integrin 
[30, 164]. We have now clarified this suggestion in RINm5F cells by combining siRNA-
mediated gene silencing and whole-cell CaV channel current analysis [200]. SR-BI siRNA 
transfection significantly reduced SR-BI at both mRNA and protein levels and sufficiently 
abolished enhancement of whole-cell CaV channel currents by ApoCIII (Fig. 8 in Paper II). 
Whole-cell CaV channel currents were smaller in SR-BI siRNA pretransfected cells incubated 
with ApoCIII (SR-BI siRNA/ApoCIII) than in those subjected to NC siRNA/apoCIII and 
similar to those in different control cells (Fig. 8e in Paper II). These control cells were 
exposed to NO siRNA/Control, NC siRNA/Control and SR-BI siRNA pretransfection 
followed by control vehicle treatment (SR-BI siRNA/Control), respectively (Fig. 8e in Paper 
II). However, whole-cell CaV channel currents were greater in NC siRNA/apoCIII-treated 
cells than in the aforementioned control cells (Fig. 8e in Paper II). SR-BI siRNA/ApoCIII 
group had significantly lower CaV channel current densities than NC siRNA/apoCIII group 
(Fig. 8f in Paper II). CaV channel current density in the former resembled, but in the latter 
appeared significantly higher than those in NO siRNA/Control, NC siRNA/Control or SR-BI 
siRNA/Control (Fig. 8f in Paper II). Undoubtedly, SR-BI gene silencing efficiently nullifies 
ApoCIII-induced hyperactivation of β cell CaV channels. In agreement with the previous 
findings that SR-BI not only physically associates with ApoCIII but also interacts with β1 
integrin in other cell types [30, 164], our data verify that SR-BI serves as a molecular bridge 
between ApoCIII and β1 integrin with regard to β cell CaV channel hyperactivation [200]. 
4.8 APOCIII HYPERACTIVATES β CELL CAV CHANNELS VIA COACTIVATION 
OF PKA AND SRC KINASE (PAPER II) 
To clarify molecular signaling pathways in ApoCIII-induced hyperactivation of β cell CaV1 
channels, we analyzed whole-cell CaV channel currents in RINm5F cells exposed to ApoCIII 
alone or together with the PKA inhibitors H-89 and PKI, the PKC inhibitor calphostin C 
(CalpC) or the Src kinase inhibitor PP2 [200]. The whole-cell CaV channel currents were 
larger in ApoCIII-treated cells than in control cells, whereas those in cells exposed to 
ApoCIII together with H-89, PKI or PP2 were in between (Fig. 3a, e and Fig. 4a in Paper II). 
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Whole-cell CaV channel currents in cells exposed to ApoCIII alone or together with CalpC 
appeared similar (Fig. 3c in Paper II). CaV channel current densities in ApoCIII group 
increased significantly in comparison to control group (Fig. 3b, d, f and Fig. 4b in Paper II). 
ApoCIII/H-89-, ApoCIII/PKI- or ApoCIII/PP2-cotreated groups manifested CaV channel 
current densities intermediate between those of ApoCIII and control groups (Fig. 3b, f and 
Fig. 4b in paper II). They were not significantly different from either ApoCIII or control 
groups in terms of CaV channel current densities. CaV channel current densities did not 
significantly differ between ApoCIII/CalpC-cotreated and ApoCIII-treated groups (Fig. 3d in 
Paper II). Furthermore, there was no significant difference between ApoCIII-untreated cells 
and those exposed to H-89, PKI, CalpC or PP2 (Supplementary Fig. S1 and S3 in Paper II). 
Undeniably, individual inhibition of PKA, PKC or Src kinase are incapable of effectively 
ablating ApoCIII-induced hyperactivation of β cell CaV channels. However, particularly 
noteworthy is that PKA or Src kinase inhibition has a tendency to counteract ApoCIII-
induced hyperactivation of β cell CaV channels [200]. 
The question immediately arises as to what happens if combined inhibition of all these 
three kinases was applied. To answer this question, we characterized the effect of co-
application of H-89, PKI, CalpC and PP2 on ApoCIII-induced hyperactivation of β cell CaV 
channels in RINm5F cells [200]. We observed that ApoCIII-treated cells displayed larger 
whole-cell CaV channel currents than control cells and cells treated with ApoCIII plus a 
protein kinase inhibitor cocktail of either PKI/CalpC/PP2 (Fig. 4a in Paper II) or H-
89/CalpC/PP2 (Fig. 5a in Paper II). Control and ApoCIII/kinase inhibitor cocktail-cotreated 
cells exhibited similar whole-cell CaV channel currents (Fig. 4a and Fig. 5a in Paper II). CaV 
channel current densities were significantly greater in ApoCIII group than in control, 
ApoCIII/PKI/CalpC/PP2 and ApoCIII/H-89/CalpC/PP2 groups (Fig. 4b and Fig. 5b in Paper 
II), whereas CaV channel current densities did not differ significantly between control and 
ApoCIII/PKI/CalpC/PP2 or ApoCIII/H-89/CalpC/PP2 groups (Fig. 4b and Fig. 5b in Paper 
II). Moreover, PKI/CalpC/PP2 or H-89/CalpC/PP2 had no significant influence on whole-cell 
CaV channel currents in ApoCIII-unexposed cells (Supplementary Fig. S2 and S3 in Paper II). 
Obviously, combined inhibition of PKA, PKC and Src kinase effectively ablates ApoCIII-
induced hyperactivation of β cell CaV channels [200]. 
The question subsequently arises as to whether coinhibition of PKA and Src kinase 
suffices to prevent ApoCIII-induced hyperactivation of β cell CaV channels. We 
circumvented the question by evaluating the influence of H-89/PP2 or PKI/PP2 cotreatments 
on ApoCIII-induced hyperactivation of β cell CaV channels in RINm5F cells [200]. We found 
that whole-cell CaV channel currents were larger in ApoCIII-treated cells than in control cells 
or cells treated with ApoCIII plus either H-89/PP2 or PKI/PP2 (Fig. 4a and Fig. 5c in Paper 
II). Similar whole-cell CaV channel currents occurred in the latter three cases (Fig. 4a and Fig. 
5c in Paper II). CaV channel current densities in the ApoCIII group significantly increased in 
comparison to control, ApoCIII/H-89/PP2 and ApoCIII/PKI/PP2 groups (Fig. 4b and Fig. 5d 
in Paper II). These latter three groups displayed similar CaV channel current densities (Fig. 4b 
and Fig. 5d in Paper II). H-89/PP2- or PKI/PP2 did not significantly alter whole-cell CaV 
channel currents in ApoCIII-unexposed cells (Supplementary Fig. S2C, D, Fig. S3A and B in 
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Paper II). Undoubtedly, coinhibition of PKA and Src kinase suffices to prevent ApoCIII-
induced hyperactivation of β cell CaV channels [200]. 
Phosphorylation of CaV channels is the foremost event in the regulation of these channels. 
We now demonstrate that complex inhibition of PKA, PKC and Src kinase ablates ApoCIII-
induced hyperactivation of β cell CaV channels and that coinhibition of PKA and Src kinase 
suffices to execute this ablation [200]. However, individual inhibition of PKA, Src kinase or 
PKC only marginally or negligibly counteracts ApoCIII-induced hyperactivation of β cell 
CaV channels [200]. Evidently, ApoCIII relies on parallel PKA and Src pathways to 
upregulate β cell CaV channels [200]. This satisfactorily fills the critical gap between 
activated β1 integrin and hyperactivated CaV1 channels in β cells [200]. 
4.9 PCS1-MEDIATED ENDOCYTOSIS REGULATES THE NUMBER OF CAV1 
CHANNELS IN THE β CELL PLASMA MEMBRANE (PAPER III) 
Endocytosis serves as a critical mechanism for density control of plasma membrane proteins 
including CaV channels [173-175, 201, 202]. It operates under direct control of a complex 
molecular network where the interaction of dynamin I with PCS1 takes center stage [174-
178]. However, the β cell endocytic machinery is rarely understood and endocytic trafficking 
of β cell CaV1 channels is not known. We therefore examined the presence and endocytic 
activity of PCS1 in β cells as well as the involvement of PCS1 in endocytic trafficking of β 
cell CaV1 channels. 
4.9.1 PCS1 is richly present in β cells (Paper III) 
We explored if PCS1 is expressed in β cells. Immunoblot analysis of different mouse tissues 
detected a clear PCS1 immunoreactive band in both brain and pancreatic islets, but not in 
exocrine pancreas, heart, kidney, liver, lung, muscle and spleen (Figure 1A in Paper III). This 
immunoreactive band also appeared in HIT-T15, INS-1, MIN6-m9 and RINm5F cells 
(Figure 1B in Paper III). Furthermore, confocal double immunofluorescence images of 
isolated mouse (Figure 2A in Paper III) and rat islets (Figure 2B in Paper III) show that all 
endocrine cells were appreciably labeled by anti-PCS1 antibodies (Figure 2Aii and 2Bii in 
Paper III) and most of them exhibited intense insulin-like immunoreactivity (-LI) (Figure 2Ai 
and 2Bi in Paper III). The majority of cells were double-labeled, but some cells were only 
recognized by anti-PCS1 antibodies (Fig. 2Aiii and 2Biii in Paper III). In cultured mouse and 
rat islet cells, all clustered (Figure 2Av and 2Bv in Paper III) and single cells (Figure 2Aviii 
and 2Bviii in Paper III) showed intense PCS1-LI, whereas only some of these cells (Figure 
2Aiv, 2Avii, 2Biv and 2Bvii in Paper III) exhibited intense insulin-LI. Both insulin-LI and 
PCS1-LI appeared in the cytoplasm with clear granule-like structures. PCS1-LI separated 
from insulin-LI (Figure 2Avi, 2Aix, 2Bvi and 2Bix in Paper III) with exception of a minor 
colocalization of PCS1-LI with insulin-LI in in the same subcellular structures (Figure 2Avi, 
2Aix, 2Bvi and 2Bix in Paper III). Evidently, the key endocytic protein PCS1 is expressed in 
all mouse and rat pancreatic islet cells including insulin-secreting β cells as well as in HIT-
T15, INS-1, MIN6-m9 and RINm5F cells. Subcellularly, it is situated in abundant granule-
like structures that are smaller than insulin-LI profiles. 
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The highly specialized secretory β cell undergoes profound exocytosis. Such profound 
exocytosis is inevitably followed by effective endocytosis to preserve β cell integrity and 
functionality, including plasma membrane protein homeostasis. However, significant efforts 
have been devoted to the understanding of insulin exocytosis [2-4]. β Cell endocytosis has 
been mostly ignored. The molecular details of the endocytic machinery in the β cell remain 
under intensive investigation. We now show for the first time that mouse and rat islet β cells 
as well as insulin-secreting cell lines express PCS1 in the cytoplasm. This is intriguing since 
this protein has previously been considered to be exclusively present in neurons [179, 180, 
203]. In addition, we also verify that PCS1 appears in abundant vesicular profiles distinct 
from insulin-containing granules. These PCS1-positive profiles are smaller than insulin-
containing granules and appear to be endocytic, endosomal or lysosomal vesicles. However, 
the identity of the subcellular organelles where PCS1 resides remains to be clarified. These 
findings provide a key “cornerstone” towards an in-depth understanding of the β cell 
endocytic machinery. 
4.9.2 PCS1 indispensably mediates β cell endocytosis (Paper III) 
To verify the role of PCS1 in regulation of β cell endocytosis, we examined the effect of 
PCS1 knockdown on β cell endocytic activity by applying siRNA-mediated gene silencing 
and live-cell confocal imaging. Transfection with two PCS1 siRNAs significantly reduced 
PCS1 protein expression in RINm5F cells (Figure 3A and B in Paper III). Internalization of 
the endocytic marker FM1-43 was significantly less in cells transfected with PCS1 siRNAs 
than in non-transfected or NC siRNA-transfected cells following either extracellular 
application of 10 mM glyceraldehyde together with 2.8 mM glucose or stimulation with 30 
mM KCl (Figure 3C-J in Paper III). Undoubtedly, downregulation of PCS1 expression 
dramatically dampens β cell endocytosis induced by a high carbohydrate challenge or high 
K+ depolarization. These findings verify that PCS1 acts as a key endocytic protein to 
indispensably mediate β cells endocytosis (Figure 7A-C in Paper III) and add a new layer of 
complexity to our understanding of the β cell enocytotic machinery. 
4.9.3 PCS1-mediated endocytosis operates as a homeostatic control system 
for the maintenance of CaV1 channel density in the β cell plasma 
membrane (Paper III) 
To clarify the physiological importance of PCS1-mediated β cell endocytosis, we evaluated 
the effect of PCS1 knockdown on the density of CaV1 channels in the β cell plasma 
membrane following 1 h incubation with 10 mM glyceraldehyde plus 2.8 mM glucose. To 
maximally activate CaV1 channels in the recorded plasma membrane patches, 10 µM Bay 
K8644, a selective CaV1 channel activator, was included in both the electrode solution and 
the extracellular solution. This ensures reliable estimation of the density of CaV1 channels in 
the β cell plasma membrane. We found that CaV1 channel number, reflected by unitary Ba2+ 
current layer, increased in plasma membrane patches of PCS1 siRNA-transfected cells 
compared to cells transfected with NC siRNA (Figure 4A). The average number of unitary 
CaV1 channels were significantly greater in plasma membrane patches of PCS1 siRNA-
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transfected cells than in those of cells transfected with NC siRNA (Figure 4B). Cells 
transfected with PCS1 siRNA did not significantly differ from NC siRNA-transfected cells in 
the open probability, mean open time and mean closed time of unitary CaV1 channels (Figure 
4B). Indeed, the PCS1 knockdown-caused impairment in β cell endocytosis leads to the 
elevated density of β cell CaV1 channels. This strongly supports that PCS1-mediated 
endocytosis preserves the homeostasis of CaV1 channels in the β cell plasma membrane. 
The integral membrane protein CaV1 channel is critical for β cell function and survival [1-
4]. A diverse range of physiological scenarios from insulin secretion to β cell survival vitally 
rely on appropriate Ca2+ influx mediated by adequate numbers of CaV1 channels in the β cell 
plasma membrane [1-4]. Inappropriate increases or decreases of CaV1 channel density in the 
β cell plasma membrane bring about intracellular Ca2+ overload or deficiency and 
consequently β cell dysfunction and even destruction [1-4]. CaV1 channels as plasma 
membrane proteins critically depend on the endocytic machinery for their internalization to 
exquisitely control their density in the plasma membrane [173-175, 201, 202]. Our 
observation that knockdown of PCS1 expression significantly elevates CaV1 channel density 
in the β cell plasma membrane convincingly pinpoints that PCS1-mediated endocytosis 
operates as a homeostatic control system for the maintenance of CaV1 channel density in the 
β cell plasma membrane. 
4.10 APOCIII ABROGATES PCS1-DEPENDENT ENDOCYTIC TRAFFICKING 
LEADING TO AN ELEVATION OF CAV1 CHANNEL DENSITY IN THE β 
CELL PLASMA MEMBRANE (PAPER IV) 
ApoCIII hyperactivates β cell CaV1 channels manifested as exaggerated elevation of both the 
conductivity and number of CaV1 channels in the β cell plasma membrane [200]. Such β cell 
CaV1 channel hyperactivation has been generally explained by SR-BI/β1 integrin-dependent 
coactivation of PKA and Src [200]. However, the specific mechanism whereby ApoCIII 
upregulates the number of CaV1 channels in the β cell plasma membrane remains elusive. To 
clarify such a mechanism, we characterized if ApoCIII interferes with endocytic activity to 
accumulate CaV1 channels in the β cell plasma membrane. 
4.10.1 ApoCIII impairs β cell endocytosis without influencing PCS1 
expression (Paper IV) 
To examine if ApoCIII interferes with endocytic trafficking of β cell CaV1 channels, we first 
evaluated the effect of ApoCIII on constitutive and regulated endocytosis in the insulin-
secreting RINm5F cells using live-cell confocal imaging of the endocytic marker FM1-43. 
ApoCIII-treated cells accumulated less FM1-43 than control cells bathed in extracellular 
solution containing neither glucose nor glyceraldehyde (Figure 1A and B in Paper IV). FM1-
43 accumulation in ApoCIII-treated group was significantly impaired in comparison to 
control group (Figure 1C in Paper IV). Moreover, ApoCIII-treated cells internalized less 
FM1-43 than control cells following stimulation with 10 mM glyceraldehyde together with 
2.8 mM glucose (Figure 1D and E in Paper IV). The fluorescence intensity of FM1-43 
internalized into ApoCIII-treated cells significantly decreased as compared to that into 
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control cells (Figure 1F in Paper IV). It is clear that ApoCIII treatment not only dampens 
constitutive β cell endocytosis but also reduces regulated β cell endocytosis induced by a high 
carbohydrate challenge. 
Endocytosis and exocytosis coordinately act to preserve protein homeostasis in the plasma 
membrane by internalizing and recruiting plasma membrane proteins including ion channels, 
respectively [173-175, 201, 202, 204]. Impaired endocytosis and consequent aberrations in 
plasma membrane protein homeostasis impair cell function and viability contributing to the 
pathogenesis of a series of diseases [205]. The aforementioned results show for the first time 
that ApoCIII impedes both constitutive and regulated β cell endocytosis. This undoubtedly 
provides a novel cellular mechanism underlying ApoCIII-induced pathological effects on β 
cells [6, 200]. 
The fact that knockdown of PCS1 effectively impairs β cell endocytosis, as presented in 
Paper III, made us wonder whether overnight ApoCIII exposure alters PCS1 expression to 
abrogate β cell endocytosis. Therefore, we examined PCS1 protein expression in RINm5F 
cells following ApoCIII incubation by using immunoblot analysis. We found that intensities 
of PCS1 and GAPDH immunoreactive bands were very similar between control and 
ApoCIII-treated samples (Figure 2A in Paper IV). The relative abundance of PCS1 protein in 
cell homogenates did not significantly differ between control vehicle incubation and ApoCIII 
exposure (Figure 2B in Paper IV). These results demonstrate that ApoCIII does not 
appreciably alter expression of β cell PCS1, but do not preclude the possibility that ApoCIII 
dampens PCS1 function. 
4.10.2 ApoCIII retains more CaV1 channels in the β cell plasma membrane by 
abrogating PCS1-dependent endocytic trafficking (Paper IV) 
Our findings that impaired β cell endocytosis occurs following either PCS1 knockdown or 
ApoCIII exposure (Figure 3 in Paper III and Figure 1 in Paper IV), the former inhibiting 
endocytic trafficking of β cell CaV1 channels (Figure 4 in Paper III), urged us to examine if 
the latter also does the same. We compared the effects of ApoCIII exposure and PCS1 
knockdown on unitary CaV1 currents in RINm5F cells following 1 h incubation with 10 mM 
glyceraldehyde plus 2.8 mM glucose. Analysis of unitary CaV1 channel currents was 
performed in NC siRNA-pretransfected cells exposed to either control vehicle (NC 
siRNA/control) or ApoCIII (NC siRNA/ApoCIII) and cells pretransfected with PCS1 
siRNAs followed by either control vehicle incubation (PCS1 siRNA/control) or ApoCIII 
exposure (PCS1 siRNA/ApoCIII). To ensure reliable estimation of the density of CaV1 
channels in the β cell plasma membrane, 10 µM Bay K8644, a selective CaV1 channel 
activator [206, 207], was added to both the electrode solution and the extracellular solution 
for maximal activation of CaV1 channels in the recorded plasma membrane patches. We 
visualized that more CaV1 channels, reflected by more layers of unitary Ba2+ currents, resided 
in plasma membrane patches attached to NC siRNA/ApoCIII cells, cells subjected to PCS1 
siRNA/control and PCS1 siRNA/ApoCIII cells compared to plasma membrane patches of 
NC siRNA/control cells (Figure 3A in Paper IV). Profiles of unitary CaV1 currents recorded 
in NC siRNA/ApoCIII, PCS1 siRNA/control and PCS1 siRNA/ApoCIII cells closely 
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resembled each other (Figure 3A in Paper IV). The average number of unitary CaV1 channels 
in NC siRNA/ApoCIII, PCS1 siRNA/control and PCS1 siRNA/ApoCIII groups was 
significantly increased in comparison to that in NC siRNA/control group (Figure 3B in Paper 
IV). This parameter did no significantly differ between NC siRNA/ApoCIII, PCS1 
siRNA/control and PCS1 siRNA/ApoCIII groups (Figure 3B in Paper IV). Importantly, 
ApoCIII exposure could no longer increase the average number of unitary CaV1 channels in 
PCS1 siRNA-pretransfected cells (Figure 3B in Paper IV). Other parameters including the 
open probability, mean open time and mean closed time of unitary CaV1 channels were 
statistically similar between these groups (Figure 3B in Paper IV). This is most likely to be 
attributed to the scenario where maximal activation of CaV1 channels with 10 µM Bay K8644 
masked the stimulatory effect of ApoCIII on CaV1 channel activity. The data reveal that 
ApoCIII accumulates CaV1 channels in the β cell plasma membrane by abrogating PCS1-
dependent endocytic trafficking. 
The above observation clearly demonstrates that PCS1 gene silencing and ApoCIII 
exposure produce similar effects on β cell CaV1 channels. Both significantly elevate the 
number of CaV1 channels in the β cell plasma membrane (Figure 4 in Paper III and Figure 3 
in Paper IV). Particularly noteworthy is that ApoCIII exposure loses its ability to accumulate 
CaV1 channels in the β cell plasma membrane following knockdown of PCS1 (Figure 3 in 
Paper IV). This demonstrates that ApoCIII accumulates CaV1 channels in the β cell plasma 
membrane by abrogating the PCS1-dependent endocytic trafficking even though ApoCIII 
does not influence PCS1 expression. CaV1 channels excessively increase their density and 
conductivity to participate in a diverse range of pathological processes [5, 6, 53, 208]. 
Understanding what pathogens and how they accumulate CaV1 channels in the cell surface 
membrane to contribute development of diseases is a long-standing challenge. The present 
work deciphers an innovative mechanism whereby ApoCIII PCS1-dependently retains 
excessive CaV1 channels in the β cell plasma membrane to account for Ca2+-dependent β cell 
destruction in diabetes development. 
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5 CONCLUSIONS 
By satisfactorily accomplishing the proposed specific aims, this PhD work draws the 
following conclusions: 
1) Functional CaV1.3 channels operate in 20 % mouse islet CaV1.2-/- β cells. They are 
characterized by a large unitary Ba2+ conductance with long-lasting openings in plasma 
membrane patches attached to islet cells exhibiting larger cell capacitance (> 7 pF) and 
insulin transcript positivity. This enables investigation of human β cell CaV1.3 channel-
related disorders such as T1D serum-induced hyperactivation of β cell CaV1.3 channels to be 
performed in the β cell-specific CaV1.2-/- mice (Figure 2). 
2) T1D serum hyperactivates both CaV1.2 and CaV1.3 channels by increasing their 
conductivity and number in the β cell plasma membrane. This pinpoints both CaV1.2 and 
CaV1.3 channels as potential druggable targets for counteraction of Ca2+ overload-induced β 
cell death (Figure 2). 
3) ApoCIII in T1D serum is electrophysiologically confirmed to act as the actual factor 
enhancing CaV channel currents in the β cell. This suggests that neutralization or depletion of 
ApoCIII in T1D serum should be considered to be a new therapy against CaV channel 
hyperactivation-driven β cell destruction (Figure 2). 
4) ApoCIII selectively hyperactivates β cell CaV1 channels through SR-BI/β1 integrin-
dependent coactivation of PKA and Src kinase without influencing β cell CaV1 channel 
expression. ApoCIII-induced hyperactivation of β cell CaV1 channels occurs due to the 
enriched density and increased activity of functional CaV1 channels in the β cell plasma 
membrane. This novel signal-transduction pathway possesses great potential as an innovative 
drug discovery platform for the prevention of Ca2+-dependent β cell death in association with 
diabetes (Figure 2). 
5) PCS1 is richly expressed in β cells and indispensably mediates β cell endocytosis. 
PCS1-mediated endocytosis operates as a homeostatic control system to fine-tune the CaV1 
channel density in the β cell plasma membrane. This adds a new layer of complexity to the 
mechanisms of β cell CaV1 channel regulation (Figure 2). 
6) ApoCIII abrogates both constitutive and regulated β cell endocytosis without 
influencing PCS1 expression. Consequently, ApoCIII abrogates PCS1-dependent endocytic 
trafficking, thereby accumulating excessive CaV1 channels in the β cell plasma membrane. 
This provides new mechanistic explanation of Ca2+-dependent β cell destruction in diabetes 
development and identifies a promising and attractive option to counteract the critical 
diabetogenic process Ca2+-dependent β cell destruction (Figure 2). 
This PhD work depicts a mechanistic picture of how ApoCIII renders CaV1 channels 
highly enriched and excessively activated in the β cell plasma membrane, thereby mediating 
pathologically exaggerated Ca2+ influx and driving Ca2+-dependent β death. These findings 
lay the foundation for novel treatment strategies for diabetes. 
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